

Document downloaded from:

<http://hdl.handle.net/10251/147736>

This paper must be cited as:

Martinez-Pardo, P.; Blay, G.; Vila, C.; Sanz-Marco, A.; Muñoz Roca, MDC.; Pedro, JR. (2019). Enantioselective Synthesis of 5-Trifluoromethyl-2-oxazolines under Dual Silver/Organocatalysis. *The Journal of Organic Chemistry*. 84(1):314-325.
<https://doi.org/10.1021/acs.joc.8b02808>



The final publication is available at

<https://doi.org/10.1021/acs.joc.8b02808>

Copyright American Chemical Society


Additional Information

Enantioselective Synthesis of 5-Trifluoromethyl-2-oxazolines under Dual Silver/Organocatalysis


Pablo Martínez-Pardo,[†] Gonzalo Blay,^{*,†} Carlos Vila,[†] Amparo Sanz-Marco,[†] M. Carmen Muñoz,[‡] and José R. Pedro^{*,†}

[†]Departament de Química Orgànica, Facultat de Química, Universitat de València, Burjassot, Valencia 46100, Spain

[‡]Departament de Física Aplicada, Universitat Politècnica de València, Valencia 46022, Spain

 Supporting Information

ABSTRACT: The first enantioselective formal [3 + 2] cycloaddition between α -isocyanoesters and trifluoromethylketones to give 5-trifluoromethyl-2-oxazolines bearing two contiguous stereogenic centers, one of them being a quaternary stereocenter substituted with a CF₃ group, has been developed. The reaction is based upon a multicatalytic approach that combines a bifunctional Brønsted base-squaramide organocatalyst and Ag⁺ as Lewis acid. The reaction could be achieved with a range of aryl and heteroaryl trifluoromethyl ketones, and the resulting oxazolines were obtained with good to excellent diastereo- and enantioselectivity.



INTRODUCTION



The 2-oxazoline moiety is present in a large number of natural products, drugs, and bioactive compounds.¹ Chiral oxazolines have also found important applications in organic synthesis as ligands in asymmetric catalysis,² as well as synthetic intermediates for 1,2-aminoalcohols and other relevant compounds.³ In recent years, the enantioselective formal [3 + 2] cycloaddition of α -isocyanoesters with carbonyl compounds has emerged as an elegant and powerful strategy for the construction of chiral substituted 2-oxazolines bearing two adjacent stereocenters and considerable success on this reaction has been obtained with aldehydes⁴ and, to a lesser extent, with ketones.⁵

On the other hand, the introduction of trifluoromethyl substituents⁶ into organic molecules has attracted great attention in the field of medicinal chemistry because of the significant impact of the trifluoromethyl group on the metabolic stability and bioavailability of drugs.⁷ For these reasons, different strategies have been devised for the synthesis of trifluoromethylated heterocycles, involving either the trifluoromethylation of nonfluorinated heterocycles⁸ or cycloaddition/cyclization reactions from trifluoromethylated building blocks.⁹ In this context, the 5-trifluoromethyl-2-oxazoline moiety is especially appealing, as it is a synthetic precursor for fluorinated nonproteinogenic amino acids and trifluoromethyl amino alcohols, which have important applications in medicinal chemistry¹⁰ and biochemical studies,¹¹ and as conformational modifiers in physiologically active proteins and enzymes.¹²

Herein, we report the enantioselective formal [3 + 2] cycloaddition between α -isocyanoesters and trifluoromethylketones to give 5-trifluoromethyl-2-oxazolines bearing two contiguous stereogenic centers, one of them being a quaternary stereocenter substituted with a CF₃ group (Scheme 1).

Although such a reaction has been diastereoselectively performed, a catalytic asymmetric version has not been developed so far, to the best of our knowledge.¹³

Scheme 1. Formal [3 + 2] Cycloaddition between Trifluoromethylketones and α -Isocyanoesters and Plausible Mode of Action of the Catalyst



RESULTS AND DISCUSSION


Recently, on the basis of a cooperative strategy previously reported by Escolano et al. for the asymmetric cycloaddition of isocyanoacetates with vinyl ketones,¹⁴ our group developed a highly catalytic enantioselective cycloaddition reaction between ketones and α -isocyanoesters using a multicatalytic approach that combined a bifunctional Brønsted base-

squaramide organocatalyst and Ag^+ as Lewis acid (Scheme 1).^{5d}

Following this approach,¹⁴ we tested the reaction of trifluoroacetophenone (1a) and methyl isocyanoacetate (2a)

mol %) and Ag_2O (5 mol %) in methyl *tert*-butylether (MTBE) at 0 °C (Table 1, see also Tables S1–S3 in the

Table 1. Bifunctional Squaramide Screening^a



entry	SQ	t (h)	yield ^b (%)	trans:cis ^c	ee ^d trans/cis (%)
1 ^e	I	72			
2	I	0.5	>95	99:1	77/57
3	II	0.5	85	99:1	−66/−28 ^f
4	III	0.5	>95	95:5	83/61
5	IV	17	>95	95:5	81/56
6	V	0.5	50	100:–	67/–
7	VI	5	>95	50:50	29/70
8	VII	0.5	>95	85:15	58/33
9	VIII	0.5	>95	79:21	78/65

^a1a (0.25 mmol), 2a (0.33 mmol), SQ (0.026 mmol), Ag_2O (0.0125 mmol), MTBE (2 mL), 0 °C. ^bYield of isolated product. ^cDetermined by ^1H NMR. ^dDetermined by HPLC over chiral chromatography phases. ^eReaction carried out in the absence of silver salt. No advance was observed after the indicated time. ^fThe opposite enantiomer was obtained.

Supporting Information). The reaction did not proceed in the absence of Ag_2O (Table 1, entry 1). On the other hand, all of the squaramides tested in combination with silver oxide provided oxazoline 3a in good yields and in a short reaction time. The *trans* diastereomer was obtained diastereoselectively in all of the cases except with squaramide VI (Table 1, entry 7). The best result in terms of enantioselectivity was obtained with squaramide III, derived from dihydroquinine and 3,5-bis(trifluoromethyl)aniline, that provided oxazoline 3a in almost quantitative yield with 95:5 dr and 83% ee for the major diastereomer (Table 1, entry 4).

A strong concentration effect was also found, with the diastereo- and enantioselectivity of the reaction increasing with

the dilution of the reaction mixture (Table 2, entries 1–3). The use of a 1:2 squaramide/ Ag_2O ratio increased the

Table 2. Effect of Concentration and Squaramide/ Ag_2O

entry	[1a] ^b	III: Ag_2O	t (h)	yield ^c (%)	trans:cis ^d	ee ^e trans (%)
1	0.13	2:1	0.5	>95	95:5	83
2	0.26	2:1	0.5	>95	87:13	75
3	0.033	2:1	4	>95	96:4	90
4 ^f	0.033	1:2	3	90	99:1	82
5 ^g	0.033	1:1	18	>95	94:6	90

^a1a (0.25 mmol), 2a (0.33 mmol), III (0.026 mmol), Ag_2O (0.0125 mmol), MTBE, 0 °C. ^bMolar concentration. ^cYield of isolated product. ^dDetermined by ^1H NMR. ^eDetermined by HPLC over chiral chromatography phases. ^fIII (0.0065 mmol). ^gIII (0.0033 mmol).

diastereoselectivity but unfortunately lowered the enantioselectivity (Table 2, entry 4). Notably, the use of a 1:1 squaramide/ Ag_2O mixture provided similar results to the initially tested 2:1 mixture, with it being possible to reduce the catalyst load to 2.5 mol % without a noticeable effect on the stereoselectivity (Table 2, entries 3 and 5).

Under the optimized conditions, the scope of the reaction of methyl isocyanoacetate (2a) and several substituted trifluoroacetophenones 1 was studied (Table 3).¹⁵ In general, the

Table 3. Enantioselective Reaction of Trifluoromethylketones and Methyl Isocyanoacetate. Substrate Scope^a

entry	1	R	t (h)	3	yield ^b (%)	trans:cis ^c	ee ^d trans (%)
1	1a	Ph	4	3a	>95	96:4	90
2	1b	4-MeC ₆ H ₄	5	3b	>95	94:6	87
3	1c	4-MeOC ₆ H ₄	3.5	3c	88	96:4	85
4	1d	4-ClC ₆ H ₄	4	3d	>95	80:20	84
5	1e	3-MeC ₆ H ₄	5	3e	>95	94:6	90
6	1f	3-MeOC ₆ H ₄	4	3f	94	92:8	88
7	1g	3-BrC ₆ H ₄	3.5	3g	95	86:14	92
8	1h	2-MeOC ₆ H ₄	16	3h	>95	99:1	85
9	1i	2-BrC ₆ H ₄	14	3i	93	85:15	70
10	1j	3,4-Cl ₂ C ₆ H ₃	16	3j	>95	77:23	85
11	1k	2-thienyl	5.5	3k	>95	92:8	90
12	1l	PhCH ₂ CH ₂	15	3l	66	86:14	81
13	1m	CH ₃	7	3m	80	92:8	82
14 ^e	1a	Ph	2	3a	>95	92:8	90


^a1a (0.25 mmol), 2a (0.33 mmol), III (0.0063 mmol), Ag_2O (0.0063 mmol), MTBE (8 mL), 0 °C. ^bYield of isolated product. ^cDetermined by ^1H NMR. ^dDetermined by HPLC over chiral chromatography phases. ^eReaction scaled up to 1.25 mmol of 1a.

presence of substituents at the *ortho* or *para* positions of the aromatic ring brought about some decrease of enantioselectivity, while the *meta*-substituted trifluoroacetophenones gave similar or higher enantiomeric excesses than ketone 1a (Table 3, entries 5–7). A negative effect of electron-withdrawing groups on the diastereoselectivity was also observed (Table 3, entries 4, 9, and 10). The heterocyclic trifluoroacetylthiophene

(1k) proved to be a suitable substrate that reacted with good diastereo- and enantioselectivity (Table 2, entry 11). Alkyl-substituted trifluoromethylketones 1l and 1m were also tested, which provided oxazolines 3l and 3m, respectively, with moderate diastereo- and enantioselectivity (Table 2, entries 12 and 13). Finally, the reaction was scaled up to 1.25 mmol of compound 1a, obtaining oxazoline 3a without any noticeable loss of efficiency, indicating the robustness of the method (Table 3, entry 14).

The configuration of the stereogenic centers in compound *trans*-3g was determined as (4*S*,5*S*) after hydrolysis and X-ray analysis of the resulting amino alcohol 7g (Scheme 2).¹⁶ For the remaining compounds 3, the stereochemistry was assigned under the assumption of a uniform mechanistic pathway.¹⁷

Scheme 2. Hydrolysis of Oxazolines 3a and 3g



^aStructure determined by X-ray analysis (see ref 16).

Next, we tested the performance of other isocyanates having different alkoxy groups (see Table S4 in the Supporting Information). *tert*-Butyl isocynoacetate seemed to promote the highest enantioselectivity using squaramide VIII instead of III. The reaction of trifluoromethylketones 1 with *tert*-butyl isocynoacetate (2b) showed a similar substrate scope as the reaction with the methyl ester. In general, the reaction took place with moderate to good diastereoselectivity and high to

4). X-ray analysis of compound 4i¹⁶ allowed us to assign the absolute stereochemistry of compounds 4 as (4*S*,5*S*), indicating a similar stereochemical pathway as the reaction with methyl isocynoacetate.¹⁷

Finally, the reaction of several trifluoromethylketones 1 with methyl 2-isocyano-2-phenylacetate (2c) to give oxazolines 5 bearing two contiguous quaternary stereocenters was achieved in the presence of squaramide VIII and Ag₂O (Table 5).¹⁸ In this case, the reaction worked better under higher concentration and with a 2:1 ratio of squaramide/Ag₂O and yielded the *cis* diastereomer as the major one.¹⁷ Fair to good diastereomeric ratios and high enantiomeric excesses were obtained for trifluoroacetophenone derivatives having electron-donating or slightly electron-withdrawing groups. However, the reaction did not proceed with *ortho*-substituted trifluoroacetophenones.

Tosylmethylisocyanide (TOSMIC) was also tested in the reaction with trifluoromethylketone 1a, although, unfortu-

Table 4. Enantioselective Reaction of Trifluoromethylketones and *tert*-Butyl Isocynoacetate. Substrate Scope^a

entry	1	R	t (d)	4	yield ^b (%)	<i>trans</i> : <i>cis</i> ^c	ee ^d _{<i>trans</i>/<i>cis</i>} (%)
1	1a	Ph	1	4a	>95	70:30	96/90
2	1b	4-MeC ₆ H ₄	7	4b	87	66:34	93/96
3	1c	4-MeOC ₆ H ₄	7	4c	>95	63:37	84/77
4	1d	4-ClC ₆ H ₄	1	4d	>95	53:47	96/90
5	1e	3-MeC ₆ H ₄	6	4e	94	76:24	97/87
6	1f	3-MeOC ₆ H ₄	4	4f	84	72:28	97/85
7	1g	3-BrC ₆ H ₄	1	4g	>95	64:36	97/90
8	1h	2-MeOC ₆ H ₄	12	4h	80	94:6	94/70
9	1i	2-BrC ₆ H ₄	3	4i ^e	>95	99:1	91/nd
10	1j	3,4-Cl ₂ C ₆ H ₃	1	4j	>95	53:47	94/85
11	1k	2-thienyl	1	4k	>95	62:38	97/91
12	1l	CH ₂ CH ₂ Ph	1	4l	83	72:28	84/87

^a1 (0.25 mmol), 2b (0.33 mmol), VIII (0.0063 mmol), Ag₂O (0.0063 mmol), MTBE (8 mL), 0 °C. ^bYield of isolated product. ^cDetermined by ¹H NMR. ^dDetermined by HPLC over chiral chromatography phases. ^eStructure determined by X-ray analysis (see ref 16).

Table 5. Enantioselective Reaction of Trifluoromethylketones and Methyl 2-Isocyano-2-phenylacetate. Substrate Scope^a

entry	1	R	t (d)	5	yield ^b (%)	<i>trans</i> : <i>cis</i> ^c	ee ^d _{<i>cis</i>} (%)
1	1a	Ph	1	5a	89	15:85	90
2	1c	4-MeOC ₆ H ₄	3	5c	42	21:79	89
3	1d	4-ClC ₆ H ₄	1	5d	>95	10:90	89
4	1n	4-BrC ₆ H ₅	2	5n	82	13:87	89
5	1e	3-MeC ₆ H ₄	1	5e	86	1:99	90
6	1f	3-MeOC ₆ H ₄	3	5f	86	15:85	89
7	1g	3-BrC ₆ H ₄	7	5g	81	2:98	88
8	1h	2-MeOC ₆ H ₄	5	5h	^e		

^a1 (0.25 mmol), 2c (0.33 mmol), VIII (0.0125 mmol), Ag₂O (0.0063 mmol), MTBE (2 mL), -20 °C. ^bYield of isolated product. ^cDetermined by ¹H NMR. ^dDetermined by HPLC over chiral chromatography phases. ^eNo advance observed after 5 days.


nately, no reaction was observed under any of the optimized conditions.

The prepared oxazolines are synthetic precursors for trifluoromethylated amino alcohols. Thus, treatment of oxazolines 3a or 3g with aqueous HCl in THF gave almost quantitative yields of hydroxyformamides 6a or 6g, respectively, with a minor decrease of ee. On the other hand, treatment of 3a or 3g with aqueous hydrochloric acid in MeOH yielded amino alcohols 7a and 7g in high yields, without erosion of enantiomeric excesses (Scheme 2).

Furthermore, oxazoline 3m, prepared in 82% ee from methyl isocynoacetate and 1,1,1-trifluoroacetone (Table 1, entry 13), upon treatment with aqueous HCl in methanol for 72 h, could be transformed into amino alcohol 7m (82% ee), a known

intermediate in the synthesis of LPC-083, which is an inhibitor of LpxC, an essential enzyme of the lipid A biosynthetic pathway in Gram-negative bacteria and a validated antibiotic target (Scheme 3).¹⁹

Scheme 3. Formal Enantioselective Synthesis of LPC-083



CONCLUSIONS

In summary, we have developed the first catalytic enantioselective formal [3 + 2] cycloaddition of trifluoromethylketones and isocyanoacetates. Using a multicatalytic approach that combines a bifunctional Brønsted base-squaramide organocatalyst and Ag⁺ as Lewis acid, we were able to obtain chiral oxazolines bearing a quaternary stereocenter substituted with a trifluoromethyl group and a contiguous tertiary or quaternary stereocenter. The reaction was broad in scope and provided a straightforward access to chiral trifluoromethylated hydroxy amino esters.

EXPERIMENTAL SECTION

General Experimental Methods. Formal [3 + 2] cycloaddition reactions were carried out in round-bottom flasks closed with a stopper. Starting materials, including trifluoromethylketones and methyl and *t*-butyl isocyanoacetate, were obtained from commercial sources. Methyl *tert*-butyl ether (MTBE) was stored over 4 Å MS until it was used. Reactions were monitored by TLC analysis using Merck Silica Gel 60 F-254 thin layer plates. Flash column chromatography was performed on Merck Silica Gel 60, 0.040–0.063 mm. Melting points were determined in capillary tubes. Unless otherwise stated, NMR spectra were run at 300 MHz for ¹H and at 75 MHz for ¹³C NMR using residual nondeuterated solvent (CHCl₃) as an internal standard (δ 7.26 and 77.0 ppm, respectively) and at 282

MHz for ¹⁹F NMR using CFCl₃ as an internal standard. Chemical shifts are given in ppm. The carbon type was determined by DEPT experiments. High resolution mass spectra (ESI) were recorded on a Q-TOF spectrometer equipped with an electrospray source with a capillary voltage of 3.5 kV (ESI). Specific optical rotations were measured using sodium light (D line 589 nm). Chiral HPLC analyses were performed in a chromatograph equipped with a UV diode-array detector using chiral stationary phase columns from Daicel or Phenomenex. Chiral GLC analyses were carried out in a chromatograph equipped with a flame ionization detector using nitrogen (1 mL/min) as carrier gas, T_{injector} = 220 °C, T_{detector} = 220 °C.

General Procedure for the Enantioselective Formal [3 + 2] Cycloaddition Reaction with Methyl Isocyanoacetate. Squaramide III (3.9 mg, 0.0063 mmol) and silver oxide (1.5 mg, 0.0063 mmol) were introduced in a 25 mL round-bottom flask followed by MTBE (8 mL) and trifluoroacetophenone 1 (0.25 mmol). The flask was closed with a stopper and introduced in an ice bath. After 5 min, methyl isocyanoacetate (2a, 30 μL, 0.33 mmol) was added and the mixture was stirred at 0 °C until consumption of the trifluoroacetophenone 1 (TLC). After this time, the reaction mixture was filtered through a short pad of silica gel and concentrated under reduced pressure. A small aliquot was analyzed by ¹H NMR to determine the diastereomer ratio and by HPLC to determine the enantiomeric excess of products 3. The remaining crude was chromatographed on

silica gel eluting with hexane:EtOAc mixtures (9:1 to 8:2) to obtain the oxazolines 3.²⁰

The racemic products were obtained by a similar procedure using N-[3,5-bis(trifluoromethyl)phenyl]-N'-(3-(dimethylamino)propyl)-squaramide as a substitute for squaramide III.

Methyl 5-Phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3a). Colorless oil (83.4 mg, >95% from 55.0 mg of 1a). HPLC (Chiracel IC, hexane:iPrOH 95:5, 0.7 mL/min): trans-(4*S*,5*S*)-3a (major diastereomer, 90% ee): major enantiomer, t_r = 12.4 min, minor enantiomer 18.3 min; cis-3a (minor diastereomer): major enantiomer, t_r = 22.6 min, minor enantiomer t_r = 28.6 min; dr trans:cis = 96:4. trans-(4*S*,5*S*)-3a (major diastereomer): [α]_D²⁵ +143.0 (c 0.30, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.44–7.43 (2H, m, Ar), 7.39–7.37 (3H, m, Ar), 7.24 (1H, d, J = 1.8 Hz, N□CHO), 5.24 (1H, d, J = 1.8 Hz, CH), 3.27 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.1 (C), 155.7 (CH), 130.7 (C), 129.6 (CH), 128.4 (CH), 125.9 (CH, q, J_{C□F} = 1.6 Hz), 123.8 (C, q, J_{C□F} = 283 Hz), 87.6 (C, q, J_{C□F} = 30 Hz), 74.2 (CH), 52.2 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.1 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₂H₁₁F₃NO₃⁺: 274.0686, found: 274.0689. cis-3a (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture: ¹H NMR (300 MHz, CDCl₃) δ 7.70–7.35 (5H, Ar), 7.16 (1H, d, J = 2.4 Hz, N□CHO), 5.14 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.91 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -76.0 (s, CF₃).

Methyl 5-(*p*-Tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3b). Colorless oil (68.9 mg, >95% from 47.0 mg of 1b). HPLC (Chiralpak AS-H, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3b (major diastereomer, 87% ee): major enantiomer, t_r = 6.0 min, minor enantiomer, t_r = 8.6 min; cis-3b (minor diastereomer): major enantiomer, t_r = 15.7 min, minor enantiomer, t_r = 17.0 min; dr trans:cis = 94:6. trans-(4*S*,5*S*)-3b (major diastereomer): [α]_D²⁵ +127.8 (c 0.58, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.32 (2H, d, J = 8.1 Hz, Ar), 7.23 (1H, d, J = 1.8 Hz, N□CHO), 7.17 (2H, d, J = 8.1 Hz, Ar), 5.22 (1H, d, J = 2.1 Hz, CH), 3.30 (3H, s, CH₃), 2.34 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.1 (C), 155.7 (CH), 139.6 (C), 129.0 (CH), 127.6 (C), 125.7 (CH, q, J_{C□F} = 1.6 Hz), 123.8 (C, q, J_{C□F} = 283 Hz), 87.5 (C, q, J_{C□F} = 30 Hz), 74.0 (CH), 52.1 (CH₃), 21.0 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.2 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₃H₁₂F₃NO₃⁺: 288.0842, found: 288.0849. cis-3b (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture: ¹H NMR (300 MHz, CDCl₃) δ 5.12 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.83 (3H, s, CH₃), 2.38 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -76.1 (s, CF₃).

Methyl 5-(4-Methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3c). Colorless oil (65.9 mg, 88% from 51.0 mg of 1c). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3c (major diastereomer, 85% ee): major enantiomer, t_r = 13.2 min, minor enantiomer, t_r = 29.0 min; cis-3c (minor diastereomer): major enantiomer, t_r = 27.9 min, minor enantiomer, t_r = 34.7 min; dr trans:cis = 96:4. trans-(4*S*,5*S*)-3c (major diastereomer): [α]_D²⁵ +122.5 (c 0.25, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.35 (2H, d, J = 8.6 Hz, Ar), 7.23 (1H, dd, J = 2.1, 0.6 Hz, N□CHO), 6.88 (2H, d, J = 9.0 Hz, Ar), 5.20 (1H, d, J = 2.1 Hz, CH), 3.80 (s, CH₃), 3.33 (s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.2 (C), 160.3 (C), 155.7 (CH), 127.3 (CH, q, J_{C□F} = 1.9 Hz), 123.8 (C, q, J_{C□F} = 283 Hz), 122.4 (C), 113.8 (CH), 87.5 (C, q, J_{C□F} = 30 Hz), 74.0 (CH), 55.2 (CH₃), 52.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.4 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₃H₁₃F₃NO₄⁺: 304.0791, found: 304.0795. cis-3c (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture: ¹H NMR (300 MHz, CDCl₃) δ 7.13 (1H, d, J = 2.4 Hz, CH), 5.11 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.89 (3H, s, CH₃), 3.82 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -76.7 (s, CF₃).

Methyl 5-(4-Chlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3d). Colorless oil (75.7 mg, >95% from 54.1 mg of 1d). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 1 mL/min):

trans-(4*S*,5*S*)-3d (major diastereomer, 84% ee): major enantiomer, t_r = 5.9 min, minor enantiomer, t_r = 8.1 min; cis-3d (minor diastereomer, 64% ee): major enantiomer, t_r = 12.7 min, minor enantiomer, t_r = 13.1 min; dr trans:cis = 80:20. trans-(4*S*,5*S*)-3d (major diastereomer): $[\alpha]_D^{25}$ +120.8 (c 0.20, CHCl₃, 84% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.37–7.35 (4H, m, Ar), 7.23 (1H, d, J = 2.1 Hz, N□CHO), 5.23 (1H, d, J = 2.1 Hz, CH), 3.33 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.9 (C), 155.6 (CH), 135.9 (C), 129.3 (C), 128.7 (CH), 127.4 (CH, q , J_{C-F} = 1.6 Hz), 123.6 (C, q , J_{C-F} = 283 Hz), 87.2 (C, q , J_{C-F} = 30.8 Hz), 74.0 (CH), 52.4 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.2 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₂H₁₀ClF₃NO₃⁺: 308.0296, found: 308.0299. cis-3d (minor diastereomer): $[\alpha]_D^{25}$ +63.5 (c 0.14, CHCl₃, 64% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.66 (2H, d, J = 8.5 Hz, Ar), 7.45 (2H, d, J = 8.5 Hz, Ar), 7.16 (1H, d, J = 2.1 Hz, CH), 5.08 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.92 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.3 (C), 154.5 (CH), 136.2 (C), 133.5 (C), 129.2 (CH), 127.9 (CH), 122.6 (C, q , J_{C-F} = 283 Hz), 87.7 (C, q , J_{C-F} = 31 Hz), 76.5 (CH), 53.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -76.0 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₂H₁₀ClF₃NO₃⁺: 308.0296, found: 308.0299.

Methyl 5-(*m*-Tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3e). Colorless oil (68.8 mg, >95% from 47.0 mg of 1e). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3e (major diastereomer, 90% ee): major enantiomer, t_r = 8.3 min, minor enantiomer, t_r = 12.0 min; cis-3e (minor diastereomer): major enantiomer, t_r = 13.8 min, minor enantiomer, t_r = 18.2 min; dr trans:cis = 94:6. trans-(4*S*,5*S*)-3e (major diastereomer): $[\alpha]_D^{25}$ +132.4 (c 0.50, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.24–7.15 (5H, m, Ar, N□CHO), 5.22 (1H, d, J = 1.8 Hz, CH), 3.30 (3H, s, CH₃), 2.36 (3H, d, J = 0.6 Hz, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.1 (C), 155.7 (CH), 138.2 (C), 130.6 (C), 130.3 (CH), 128.3 (CH), 126.4 (CH, q , J_{C-F} = 1.8 Hz), 123.8 (C, q , J_{C-F} = 283 Hz), 122.9 (CH, q , J_{C-F} = 1.9 Hz), 87.6 (C, q , J_{C-F} = 30 Hz), 74.1 (CH), 52.2 (CH₃), 21.4 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.1 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₃H₁₃F₃NO₃⁺: 288.0842, found: 288.0845. cis-3e (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 5.13 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.83 (3H, s, CH₃), 2.41 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.8 (s, CF₃).

Methyl 5-(3-Methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3f). Colorless oil (71.3 mg, 94% from 51.0 mg of 1f). HPLC (Chiralpak AS-H, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3f (major diastereomer, 88% ee): major enantiomer, t_r = 7.3 min, minor enantiomer, t_r = 10.0 min; cis-3f (minor diastereomer): major enantiomer, t_r = 21.8 min, minor enantiomer, t_r = 19.9 min; dr trans:cis = 92:8. trans-(4*S*,5*S*)-3f (major diastereomer): $[\alpha]_D^{25}$ -26.7 (c 0.56, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.29 (1H, t, J = 8.4 Hz, Ar), 7.22 (1H, d, J = 2.1 Hz, N□CHO), 7.01–6.98 (2H, m, Ar), 6.92–6.90 (1H, m, Ar), 5.22 (1H, d, J = 1.8 Hz, CH), 3.80 (3H, s, CH₃), 3.33 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.1 (C), 159.5 (C), 155.7 (CH), 132.1 (C), 129.5 (CH), 123.7 (C, q , J_{C-F} = 283 Hz), 118.1 (CH, q , J_{C-F} = 2.2 Hz), 114.9 (CH), 111.9 (CH, q , J_{C-F} = 1.7 Hz), 87.5 (C, q , J_{C-F} = 30 Hz), 74.1 (CH), 55.3 (CH₃), 52.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.2 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₃H₁₃F₃NO₃⁺: 304.0791, found: 304.0794. cis-3f (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.14 (1H, d, J = 2.1 Hz, N□CHO), 5.13 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.91 (3H, s, CH₃), 3.84 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.9 (s, CF₃).

Methyl 5-(3-Bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3g). Colorless oil (83.0 mg, 95% from 63.3 mg of 1g). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3g (major diastereomer, 92% ee): major enantiomer, t_r = 7.3 min, minor enantiomer, t_r = 9.8 min; cis-3g (minor diastereomer): major enantiomer, t_r = 14.5 min, minor enantiomer, t_r = 18.3 min; dr trans:cis = 86:14. trans-(4*S*,5*S*)-3g (major diastereomer): $[\alpha]_D^{25}$

+107.7 (c 0.66, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.62 (1H, s, Ar), 7.53 (1H, ddd, J = 8.0, 1.9, 1.1 Hz, Ar), 7.38 (1H, brd, J = 8.0 Hz, Ar), 7.25 (1H, t, J = 8.0 Hz, Ar), 7.23 (1H, d, J = 1.8 Hz, N□CHO), 5.23 (1H, d, J = 2.1 Hz, CH), 3.36 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.8 (C), 155.5 (CH), 132.9 (C), 132.8 (CH), 129.9 (CH), 129.1 (CH, q , J_{C-F} = 1.7 Hz), 125.4 (C, q , J_{C-F} = 283 Hz), 124.6 (CH, q , J_{C-F} = 1.7 Hz), 122.6 (C), 86.9 (C, q , J_{C-F} = 30 Hz), 74.1 (CH), 52.4 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.1 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₂H₁₀BrF₃NO₃⁺: 351.9791, found: 351.9791. cis-3g (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.15 (1H, d, J = 2.1 Hz, N□CHO), 5.08 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.90 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.8 (s, CF₃).

Methyl 5-(2-Methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3h). White solid (86.3 mg, >95% from 58.1 mg of 1h). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3h (major diastereomer, 85% ee): major enantiomer, t_r = 11.6 min, minor enantiomer, t_r = 15.9 min; cis-3h (minor diastereomer): major enantiomer, t_r = 17.2 min, minor enantiomer, t_r = 26.9 min; dr trans:cis = 99:1. trans-(4*S*,5*S*)-3h (major diastereomer): mp 129–130 °C; $[\alpha]_D^{25}$ +228.1 (c 0.41, CHCl₃, for the diastereomer mixture, dr = 98:2); ¹H NMR (300 MHz, CDCl₃) δ 7.61 (1H, dd, J = 7.8, 1.8 Hz, Ar), 7.38 (1H, td, J = 7.5, 1.8 Hz, Ar), 7.13 (1H, d, J = 2.1 Hz, N□CHO), 7.05 (1H, td, J = 7.8, 1.2 Hz, Ar), 6.86 (1H, dd, J = 8.1, 0.9 Hz, Ar), 5.28 (1H, d, J = 2.1 Hz, CH), 3.75 (3H, s, CH₃), 3.54 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 167.7 (C), 155.3 (C), 155.2 (CH), 130.9 (CH), 128.8 (CH), 123.8 (C, q , J_{C-F} = 283 Hz), 120.9 (CH), 119.8 (C), 110.3 (CH), 86.9 (C, q , J_{C-F} = 30.8 Hz), 72.8 (CH), 54.7 (CH₃), 52.1 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -81.9 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₃H₁₃F₃NO₃⁺: 304.0791, found: 304.0791.

Methyl 5-(2-Bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3i). Colorless oil (81.7 mg, 93% from 63.3 mg of 1i). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3i (major diastereomer, 70% ee): major enantiomer, t_r = 8.9 min, minor enantiomer, t_r = 12.6 min; cis-3i (minor diastereomer): major enantiomer, t_r = 17.8 min, minor enantiomer, t_r = 24.3 min; dr trans:cis = 85:15. trans-(4*S*,5*S*)-3i (major diastereomer): $[\alpha]_D^{25}$ +150.9 (c 0.43, CHCl₃, for the diastereomer mixture, dr = 85:15); ¹H NMR (500 MHz, CDCl₃, 50 °C) δ 7.90 (1H, unresolved d, Ar), 7.73 (1H, dd, J = 8.0, 1.3 Hz, Ar), 7.52 (1H, td, J = 8.0, 1.0 Hz, Ar), 7.37 (1H, td, J = 8.0, 1.5 Hz, Ar), 7.27 (1H, d, J = 2.0 Hz, N□CHO), 5.62 (1H, s, CH), 3.72 (3H, s, CH₃); ¹³C{¹H} NMR (125 MHz, CDCl₃, 50 °C) δ 167.4 (C), 155.0 (CH), 136.3 (C), 134.6 (br CH), 130.8 (CH), 130.4 (CH), 127.6 (CH), 123.7 (C, q , J_{C-F} = 283 Hz), 120.8 (C), 88.8 (C, q , J_{C-F} = 29 Hz), 72.9 (CH), 52.6 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -79.4 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₁H₉BrF₃NO₃⁺: 351.9791, found: 351.9798. cis-3i (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.93 (br d, J = 8.1 Hz, Ar), 7.83 (1H, dd, J = 8.1, 1.3 Hz, Ar), 7.52 (1H, td, J = 8.0, 1.0 Hz, Ar), 7.39 (1H, td, J = 8.0, 1.5 Hz, Ar), 7.26 (1H, d, J = 2.0 Hz, N□CHO), 5.62 (1H, s, CH), 3.98 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.2 (s, CF₃).

Methyl 5-(3,4-Dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3j). Yellow oil (90.1 mg, >95% from 64.1 mg of 1j). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-3j (major diastereomer, 85% ee): major enantiomer, t_r = 6.4 min, minor enantiomer, t_r = 8.7 min; cis-3j (minor diastereomer): major enantiomer, t_r = 16.4 min, minor enantiomer, t_r = 19.6 min; dr trans:cis = 77:23. trans-(4*S*,5*S*)-3j (major diastereomer): $[\alpha]_D^{25}$ +105.0 (c 0.92, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.56 (1H, d, J = 2.3 Hz, Ar), 7.46 (1H, d, J = 8.7 Hz, Ar), 7.27 (1H, ddd, J = 8.4, 2.1, 0.9 Hz, Ar), 7.22 (1H, d, J = 1.8 Hz, N□CHO), 5.22 (1H, d, J = 1.8 Hz, CH), 3.40 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz) δ 166.7 (C), 155.4 (CH), 134.3 (C), 133.1 (C), 131.0 (C), 130.5 (CH), 128.2 (CH, q , J_{C-F} = 1.8 Hz), 125.4 (CH, q , J_{C-F} = 1.7 Hz), 125.2

(C, q, $J_{\text{C-OF}} = 283$ Hz), 86.6 (C, q, $J_{\text{C-OF}} = 29$ Hz), 74.0 (CH), 52.5 (CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -80.2 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_9\text{Cl}_2\text{F}_3\text{NO}_3^+$: 341.9906, found: 341.9909. *cis*-3j (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ^1H NMR (300 MHz, CDCl_3) δ 7.14 (1H, d, $J = 2.1$ Hz, $\text{N}\square\text{CHO}$), 5.05 (1H, dd, $J = 2.1, 0.9$ Hz, CH), 3.91 (3H, s, CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -76.0 (s, CF₃).

Methyl 5-(Thiophen-2-yl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3k). Yellow oil (80.1 mg, >95% from 52.3 mg of 3k). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): *trans*-(4*S*,5*S*)-3k (major diastereomer, 90% ee): major enantiomer, $t_r = 10.0$ min, minor enantiomer, $t_r = 13.8$ min; *cis*-3k (minor diastereomer): major enantiomer, $t_r = 17.6$ min, minor enantiomer, $t_r = 22.1$ min; dr *trans*:*cis* = 92:8. *trans*-(4*S*,5*S*)-3k (major diastereomer): $[\alpha]_D^{25} +48.0$ (c 0.79, CHCl_3 , for the diastereomer mixture); ^1H NMR (300 MHz, CDCl_3) δ 7.36 (1H, dd, $J = 5.1, 1.5$ Hz, Ar), 7.19 (1H, dd, $J = 2.1, 0.6$ Hz, $\text{N}\square\text{CHO}$), 7.10–7.08 (1H, m, Ar), 7.03 (1H, dd, $J = 5.1, 3.9$ Hz, Ar), 5.22 (1H, d, $J = 2.1$ Hz, CH), 3.41 (3H, s, CH₃); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 166.7 (C), 155.1 (CH), 132.7 (C), 127.5 (CH), 126.9 (CH), 126.8 (CH, q, $J_{\text{C-OF}} = 2.1$ Hz), 123.2 (C, q, $J_{\text{C-OF}} = 283$ Hz), 86.3 (C, q, $J_{\text{C-OF}} = 32$ Hz), 74.6 (CH), 52.4 (CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -81.5 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{10}\text{H}_9\text{F}_3\text{NO}_3\text{S}^+$: 280.0250, found: 280.0253. *cis*-3k (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ^1H NMR (300 MHz, CDCl_3) δ 7.12 (1H, d, $J = 2.1$ Hz, $\text{N}\square\text{CHO}$), 5.19 (1H, dd, $J = 2.1, 0.6$ Hz, CH), 3.89 (3H, s, CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -76.4 (s, CF₃).

Methyl 5-Phenethyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3l). Yellow oil (50.1 mg, 66% from 51.0 mg of 1l). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): *trans*-(4*S*,5*S*)-3l (major diastereomer, 81% ee): major enantiomer, $t_r = 7.9$ min, minor enantiomer, $t_r = 19.6$ min; *cis*-3l (minor diastereomer): major enantiomer, $t_r = 39.5$ min, minor enantiomer, $t_r = 28.4$ min; dr *trans*:*cis* = 86:14. *trans*-(4*S*,5*S*)-3l (major diastereomer): $[\alpha]_D^{25} +17.5$ (c 0.81, CHCl_3 , for the diastereomer mixture); ^1H NMR (300 MHz, CDCl_3) δ 7.30–7.26 (4H, m, Ar), 7.13–7.10 (1H, m, Ar), 7.03 (1H, d, $J = 2.4$ Hz, $\text{N}\square\text{CHO}$), 4.98 (1H, d, $J = 2.4$ Hz, CH), 3.81 (3H, s, CH₃), 2.78–2.55 (2H, m, CH₂), 2.33–2.06 (2H, m, CH₂); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 168.1 (C), 155.2 (CH), 139.9 (C), 128.6 (CH), 128.1 (CH), 126.4 (CH), 124.2 (C, q, $J_{\text{C-OF}} = 283$ Hz), 85.7 (C, q, $J_{\text{C-OF}} = 30.1$ Hz), 71.3 (CH), 52.8 (CH₃), 31.4 (CH₂), 28.6 (CH₂); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -80.7 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{15}\text{F}_3\text{NO}_3^+$: 302.0999, found: 302.1004. *cis*-3l (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ^1H NMR (300 MHz, CDCl_3) δ 4.82 (1H, d, $J = 2.1$ Hz, CH), 3.81 (3H, s, CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -76.3 (s, CF₃).

Methyl 5-Methyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (3m). Volatile colorless oil (42.2 mg, 80% from 28.1 mg of 1m). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 1 mL/min): *trans*-(4*S*,5*S*)-3m (major diastereomer 82%): major enantiomer, $t_r = 6.9$ min, minor enantiomer, $t_r = 8.5$ min; *cis*-3m (minor diastereomer): major enantiomer, $t_r = 12.7$ min, minor enantiomer, $t_r = 14.0$ min; dr *trans*:*cis* = 92:8. *trans*-(4*S*,5*S*)-3m (major diastereomer): $[\alpha]_D^{25} +75.3$ (c 0.33, CHCl_3 , for the diastereomer mixture); ^1H NMR (300 MHz, CDCl_3) δ 6.97 (1H, d, $J = 1.5$ Hz, $\text{N}\square\text{CHO}$), 4.88 (1H, d, $J = 2.5$ Hz, CH), 3.79 (3H, s, CH₃), 1.49 (3H, m, CH₃); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 168.0 (C), 155.5 (CH), 124.0 (C, q, $J_{\text{C-OF}} = 283$ Hz), 83.9 (C, q, $J_{\text{C-OF}} = 32$ Hz), 71.3 (CH), 52.7 (CH₃), 15.3 (CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -83.3 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_7\text{H}_9\text{F}_3\text{NO}_3^+$: 212.0529, found: 212.0536. *cis*-3m (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ^1H NMR (300 MHz, CDCl_3) δ 4.62 (1H, dd, $J = 2.2, 0.6$ Hz, CH), 3.79 (3H, s, CH₃), 1.74 (3H, s, CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282

General Procedure for the Enantioselective Formal [3 + 2] Cycloaddition Reaction with *tert*-Butyl Isocynoacetate. Squaramide VIII (6.8 mg, 0.0125 mmol) and silver oxide (1.5 mg, 0.0063 mmol) were introduced in a round-bottom flask followed by MTBE (8 mL) and trifluoroacetophenone 1 (0.25 mmol). The flask was closed with a stopper and introduced in an ice bath. After 5 min, *tert*-butyl isocynoacetate (2h, 48 μL , 0.33 mmol) was added and the mixture was stirred at 0 $^\circ\text{C}$ until consumption of the trifluoroacetophenone 1 (TLC). After this time, the reaction mixture was filtered through a short pad of silica gel and concentrated under reduced pressure. A small aliquot was analyzed by ^1H NMR to determine the diastereomer ratio and by HPLC to determine the enantiomeric excess of products 4. The remaining crude was chromatographed on silica gel eluting with hexane:EtOAc mixtures (9:1 to 8:2) to obtain

compounds 4.

The racemic product was obtained using a similar procedure using the catalyst 3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-((3-(dimethylamino)propyl)amino)cyclobut-3-ene-1,2-dione and silver oxide.

tert-Butyl 5-Phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4a). Colorless oil (102.2 mg, >95% from 57.3 mg of 1a). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 0.7 mL/min): *trans*-(4*S*,5*S*)-4a (major diastereomer, 96% ee): major enantiomer, $t_r = 7.2$ min, minor enantiomer, $t_r = 8.5$ min; *cis*-4a (minor diastereomer, 90% ee): major enantiomer, $t_r = 11.1$ min, minor enantiomer, $t_r = 15.2$ min; dr *trans*:*cis* = 70:30. *trans*-(4*S*,5*S*)-4a (major diastereomer): $[\alpha]_D^{25} +178.1$ (c 1.15, CHCl_3 , 96% ee); ^1H NMR (CDCl_3 , 300 MHz) δ 7.50–7.46 (2H, m, Ar), 7.39–7.37 (3H, m, Ar), 7.20 (1H, d, $J = 1.8$ Hz, $\text{N}\square\text{CHO}$), 5.08 (1H, d, $J = 1.8$ Hz, CH), 1.03 (9H, s, CH₃); $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3 , 75 MHz) δ 165.3 (C), 155.3 (CH), 131.0 (C), 129.4 (CH), 128.4 (CH), 126.4 (CH, q, $J_{\text{C-OF}} = 2.0$ Hz), 123.9 (C, q, $J_{\text{C-OF}} = 284$ Hz), 87.6 (C, q, $J_{\text{C-OF}} = 30$ Hz), 82.7 (C), 74.6 (CH), 27.1 (CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -80.3 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{17}\text{F}_3\text{NO}_3^+$: 316.1155, found: 316.1154. *cis*-4a (minor diastereomer): $[\alpha]_D^{25} +77.2$ (c 0.23, CHCl_3 , 90% ee); ^1H NMR (300 MHz, CDCl_3) δ 7.72–7.69 (2H, m, Ar), 7.46–7.44 (3H, m, Ar), 7.12 (1H, d, $J = 2.4$ Hz, $\text{N}\square\text{CHO}$), 5.02 (1H, dd, $J = 2.1, 0.6$ Hz, CH), 1.58 (9H, s, CH₃); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 165.7 (C), 154.0 (CH), 135.6 (C), 129.7 (CH), 128.7 (CH), 128.6 (C, q, $J_{\text{C-OF}} = 283$ Hz), 126.4 (CH), 123.0 (C, q, $J_{\text{C-OF}} = 283$ Hz), 87.9 (C, q, $J_{\text{C-OF}} = 30.7$ Hz), 83.6 (C), 77.4 (CH), 27.7 (CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -75.0 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{17}\text{F}_3\text{NO}_3^+$: 316.1155, found: 316.1154.

tert-Butyl 5-(*p*-Tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4b). White solid (71.7 mg, 87% from 47.0 mg of 1b). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): *trans*-(4*S*,5*S*)-4b (major diastereomer, 93% ee): major enantiomer, $t_r = 6.9$ min, minor enantiomer, $t_r = 9.4$ min; *cis*-4b (minor diastereomer, 96% ee): major enantiomer, $t_r = 12.2$ min, minor enantiomer, $t_r = 18.3$ min; dr *trans*:*cis* = 66:34. *trans*-(4*S*,5*S*)-4b (major diastereomer): mp: 63–65 $^\circ\text{C}$; $[\alpha]_D^{25} +153.3$ (c 0.96, CHCl_3 , 93% ee); ^1H NMR (300 MHz, CDCl_3) δ 7.35 (2H, d, $J = 8.1$ Hz, Ar), 7.19 (1H, d, $J = 2.1$ Hz, $\text{N}\square\text{CHO}$), 7.18 (2H, d, $J = 8.1$ Hz, Ar), 5.05 (1H, d, $J = 2.1$ Hz, CH), 2.33 (3H, d, $J = 0.9$ Hz, CH₃), 1.05 (9H, s, CH₃); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ 165.4 (C), 155.3 (CH), 139.4 (C), 129.0 (CH), 128.0 (C), 126.3 (CH, q, $J_{\text{C-OF}} = 1.7$ Hz), 123.9 (C, q, $J_{\text{C-OF}} = 283$ Hz), 87.6 (C, q, $J_{\text{C-OF}} = 30$ Hz), 82.6 (C), 74.5 (CH), 27.1 (CH), 21.0 (CH); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl_3) δ -80.4 (s, CF₃); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{19}\text{F}_3\text{NO}_3^+$: 330.1312, found: 330.1316. *cis*-4b (minor diastereomer): colorless oil; $[\alpha]_D^{25} +84.8$ (c 1.09, CHCl_3 , 96% ee); ^1H NMR (300 MHz, CDCl_3) δ 7.57 (2H, d, $J = 8.1$ Hz, Ar), 7.26 (2H, d, $J = 8.1$ Hz, Ar), 7.10 (1H, d, $J = 2.1$ Hz, $\text{N}\square\text{CHO}$), 5.00 (1H, dd, $J = 2.4, 0.9$ Hz, CH), 2.38 (3H, s, CH₃), 1.57 (9H, s, CH₃); $^{13}\text{C}\{^1\text{H}\}$ NMR (75 MHz, CDCl_3) δ -77.7 (s, CF₃).

CDCl₃) δ 165.8 (C), 154.0 (CH), 139.7 (C), 132.6 (C), 129.4 (CH), 126.3 (CH), 123.0 (C, q, $J_{\text{C-F}} = 283$ Hz), 87.9 (C, q, $J_{\text{C-F}} = 30.1$ Hz), 83.5 (C), 27.7 (CH₃), 21.1 (CH₃); $^{19}\text{F}\{^1\text{H}\}$ NMR (282 MHz, CDCl₃) δ -75.1 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₆H₁₉F₃NO₃⁺: 330.1312, found: 330.1316.

tert-Butyl (4S,5S)-5-(4-Methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4c). Colorless oil (84.0 mg, >95% from 51.2 mg of 1c). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 0.7 mL/min): trans-(4S, 5S)-4c (major diastereomer, 84%): major enantiomer, t_r = 8.7 min, minor enantiomer, t_r = 14.2 min; cis-4c (minor diastereomer, 77% ee): major enantiomer, t_r = 16.8 min, minor enantiomer, t_r = 20.9 min; dr trans:cis = 63:37. trans-(4S, 5S)-4c (major diastereomer): $[\alpha]_D^{25}$ +127.3 (c 0.82, CHCl₃, 84% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.39 (2H, d, J = 9.0, Ar), 7.18 (1H, d, J = 1.8 Hz, N□CHO), 6.89 (2H, d, J = 9.0 Hz, Ar), 5.04 (1H, d, J = 1.8 Hz, CH), 3.79 (3H, s, CH₃), 1.08 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.5 (C), 160.4 (C), 155.3 (CH), 127.9 (CH, q, $J_{\text{C-OF}}$ = 1.8 Hz), 123.9 (C, q, $J_{\text{C-OF}}$ = 284 Hz), 122.9 (C), 113.8 (CH), 87.5 (C, q, $J_{\text{C-OF}}$ = 29 Hz), 82.7 (C), 74.5 (CH), 55.3 (CH₃), 27.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.5 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 346.1261, found: 346.1251. cis-4c (minor diastereomer): $[\alpha]_D^{25}$ +47.1 (c 0.75, CHCl₃, 77% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.61 (2H, d, J = 9.0 Hz, Ar), 7.10 (1H, d, J = 2.4 Hz, N□CHO), 6.96 (2H, d, J = 9.0 Hz, Ar), 5.00 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.83 (3H, s, CH₃), 1.57 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.8 (C), 160.5 (C), 154.0 (CH), 127.8 (CH), 127.4 (C), 123.0 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 114.1 (CH), 87.8 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 83.5 (C), 77.4 (CH), 55.3 (CH₃), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.4 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 346.1261, found: 346.1251.

tert-Butyl 5-(4-Chlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4d). Colorless oil (103.4 mg, >95% from 62.0 mg of 1d). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4d (major diastereomer, 96% ee): major enantiomer, t_r = 7.6 min, minor enantiomer, t_r = 9.0 min; cis-4d (minor diastereomer, 90% ee): major enantiomer, t_r = 16.7 min, minor enantiomer, t_r = 18.5 min; dr trans:cis = 53:47. trans-(4S,5S)-4d (major diastereomer): $[\alpha]_D^{25}$ +81.7 (c 0.30, CHCl₃, 96% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.43 (2H, d, J = 9.0 Hz, Ar), 7.37 (2H, d, J = 9.0 Hz, Ar), 7.19 (1H, d, J = 2.0 Hz, N□CHO), 5.07 (1H, d, J = 2.0 Hz, CH), 1.08 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.2 (C), 155.2 (CH), 135.8 (C), 129.5 (C), 128.7 (CH), 128.0 (CH, q, $J_{\text{C-OF}}$ = 1.9 Hz), 123.7 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 87.5 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 83.1 (C), 74.6 (CH), 27.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.4 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₆ClF₃NO₄⁺: 350.0765, found: 350.0757. cis-4d (minor diastereomer): $[\alpha]_D^{25}$ +48.6 (c 0.46, CHCl₃, 90% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.64 (2H, d, J = 9.0 Hz, Ar), 7.42 (2H, d, J = 9.0 Hz, Ar), 7.10 (1H, d, J = 2.1 Hz, N□CHO), 4.96 (1H, dd, J = 2.1, 0.6 Hz, CH), 1.57 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.4 (C), 153.9 (CH), 136.0 (C), 133.9 (C), 129.0 (CH), 127.9 (CH), 122.8 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 87.5 (C, q, $J_{\text{C-OF}}$ = 31 Hz), 83.9 (C), 77.4 (CH), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.2 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₆ClF₃NO₄⁺: 350.0765, found: 350.0757.

tert-Butyl 5-(m-Tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4e). Colorless oil (77.1 mg, 94% from 47.2 mg of 1e). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4e (major diastereomer, 97% ee): major enantiomer, t_r = 5.6 min, minor enantiomer, t_r = 6.7 min; cis-4e (minor diastereomer, 87% ee): major enantiomer, t_r = 10.0 min, minor enantiomer, t_r = 14.4 min; dr trans:cis = 76:24. trans-(4S,5S)-4e (major diastereomer): $[\alpha]_D^{25}$ +166.8 (c 0.55, CHCl₃, 97% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.27–7.25 (3H, m, Ar), 7.21–7.18 (2H, m, Ar, NCHO), 5.06 (1H, d, J = 2.1 Hz, CH), 2.35 (3H, s, CH₃), 1.04 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.3 (C), 155.3 (CH), 138.0 (C), 130.9 (C), 130.1 (CH), 128.3 (CH), 126.9 (CH, q, $J_{\text{C-OF}}$ = 2.0 Hz), 123.9 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 123.5 (CH, q, $J_{\text{C-OF}}$ = 1.9 Hz), 87.6 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 82.5 (C), 74.6 (CH), 27.1 (CH₃), 21.4 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.3 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 330.1312, found: 330.1308. cis-4e (minor diastereomer): $[\alpha]_D^{25}$ +52.9 (c 0.98, CHCl₃, 87% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.51 (1H, s, Ar), 7.49 (1H, d, J = 9.0 Hz, Ar), 7.33 (1H, td, J = 7.5, 0.6 Hz, Ar), 7.25 (1H, br d, J = 7.6 Hz,

Ar), 7.11 (1H, d, J = 2.1 Hz, N□CHO), 5.01 (1H, dd, J = 2.4, 0.9 Hz, CH), 2.40 (3H, s, CH₃), 1.58 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.7 (C), 154.0 (CH), 138.5 (C), 135.5 (C), 130.4 (CH), 128.6 (CH), 126.9 (CH), 123.4 (CH), 123.0 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 87.9 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 83.5 (CH), 77.4 (CH), 27.7 (CH₃), 21.5 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.0 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 330.1312, found: 330.1308.

tert-Butyl 5-(3-Methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4f). Colorless oil (72.7 mg, 84% from 51.1 mg of 1f). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4f (major diastereomer, 97% ee): major enantiomer, t_r = 6.8 min, minor enantiomer, t_r = 16.0 min, cis-4f (minor diastereomer, 85% ee): major enantiomer, t_r = 13.2 min, minor enantiomer, t_r = 20.9 min; dr trans:cis = 72:28. trans-(4S,5S)-4f (major diastereomer): $[\alpha]_D^{25}$ +164.7 (c 0.49, CHCl₃, 97% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.28 (1H, td, J = 8.0, 0.6 Hz, Ar), 7.19 (1H, dd, J = 1.9, 0.5 Hz, N□CHO), 7.06 (1H, m, Ar), 7.00 (1H, m, Ar), 6.91 (1H, ddd, J = 8.2, 2.5, 0.9 Hz, Ar), 5.06 (1H, d, J = 1.9 Hz, CH), 3.80 (3H, s, CH₃), 1.07 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.3 (C), 159.5 (C), 155.3 (CH), 132.3 (C), 129.5 (CH), 123.8 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 118.6 (CH, q, $J_{\text{C-OF}}$ = 2.0 Hz), 114.8 (CH), 112.5 (CH, q, $J_{\text{C-OF}}$ = 1.8 Hz), 87.5 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 82.7 (C), 74.6 (CH), 55.3 (CH₃), 27.2 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.4 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 346.1261, found: 346.1260. cis-4f (minor diastereomer): $[\alpha]_D^{25}$ +56.9 (c 0.77, CHCl₃, 85% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.36 (1H, t, J = 7.8, Ar), 7.30–7.24 (2H, m, Ar), 7.11 (1H, d, J = 2.1 Hz, N□CHO), 6.96 (1H, ddd, J = 8.1, 2.6, 1.2 Hz, Ar), 5.02 (1H, dd, J = 2.1, 0.6 Hz, CH), 3.84 (3H, s, CH₃), 1.57 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.7 (C), 159.7 (C), 154.0 (CH), 132.2 (C), 129.8 (CH), 122.9 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 118.5 (CH), 115.1 (CH), 112.2 (CH), 87.9 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 83.6 (C), 77.4 (CH), 55.4 (CH₃), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -74.9 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 346.1261, found: 346.1260.

tert-Butyl 5-(3-Bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4g). Colorless oil (95.7 mg, >95%, from 63.5 mg of 1g). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 0.5 mL/min): trans-(4S,5S)-4g (major diastereomer, 90% ee): major enantiomer, t_r = 10.8 min, minor enantiomer, t_r = 12.7 min, cis-4g (minor diastereomer, 97% ee): major enantiomer, t_r = 24.3 min, minor enantiomer, t_r = 35.5 min; dr trans:cis = 64:36. trans-(4S,5S)-4g (major diastereomer): $[\alpha]_D^{25}$ +143.5 (c 0.52, CHCl₃, 97% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.63 (1H, bs, Ar), 7.52 (1H, ddd, J = 7.9, 1.9, 1.0 Hz, Ar), 7.42 (1H, m, Ar), 7.26 (1H, td, J = 8.1, 0.6 Hz, Ar), 7.19 (1H, dd, J = 2.1, 0.6, N□CHO), 5.06 (1H, d, J = 2.0 Hz, CH), 1.10 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.1 (C), 155.1 (CH), 133.2 (C), 132.6 (CH), 130.0 (CH), 129.5 (CH, q, $J_{\text{C-OF}}$ = 1.8 Hz), 125.1 (CH, q, $J_{\text{C-OF}}$ = 2.0 Hz), 123.6 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 122.6 (C), 86.9 (C, q, $J_{\text{C-OF}}$ = 30 Hz), 83.1 (C), 74.6 (CH), 27.2 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -80.3 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₆BrF₃NO₄⁺: 394.0260, found: 394.0251. cis-4g (minor diastereomer): $[\alpha]_D^{25}$ +42.7 (c 1.39, CHCl₃, 90% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.89 (1H, bs, Ar), 7.64 (1H, br d, J = 8.0 Hz, Ar), 7.58 (1H, ddd, J = 8.0, 1.9, 1.0 Hz, Ar), 7.33 (1H, t, J = 7.9 Hz, Ar), 7.11 (1H, d, J = 2.3 Hz, N□CHO), 4.96 (1H, dd, J = 2.3, 0.9 Hz, CH), 1.58 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.2 (C), 153.9 (CH), 137.6 (C), 132.9 (CH), 130.3 (CH), 129.7 (CH), 125.1 (CH), 122.8 (C), 122.7 (C, q, $J_{\text{C-OF}}$ = 283 Hz), 87.2 (C, q, $J_{\text{C-OF}}$ = 30.1 Hz), 83.9 (C), 77.3 (CH), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -75.1 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₆BrF₃NO₄⁺: 394.0260, found: 394.0251.

tert-Butyl 5-(2-Methoxyphenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4h). White solid (69.0 mg, 80% from 51.0 mg of 1h). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4S,5S)-4h (major diastereomer, 94% ee): major enantiomer, t_r = 7.0 min, minor enantiomer, t_r = 23.0 min; cis-4h (minor diastereomer, 70% ee): major enantiomer, t_r = 19.9 min,

minor enantiomer, $t_r = 30.2$ min; dr trans:cis = 94:6. trans-(4*S*,5*S*)-4h (major diastereomer): Mp: 76–79 °C; $[\alpha]_D^{25} +252.5$ (c 0.78, CHCl₃, 94% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.57 (1H, dd, J = 7.8, 1.8 Hz, Ar), 7.37 (1H, ddd, J = 8.4, 7.5, 1.8 Hz, Ar), 7.09 (1H, d, J = 2.0 Hz, N□CHO), 7.02 (1H, td, J = 7.5, 1.0 Hz, Ar), 6.85 (1H, dd, J = 8.4, 1.2 Hz, Ar), 5.12 (1H, d, J = 2.0 Hz, CH), 3.76 (3H, s, CH₃), 1.12 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.6 (C), 155.7 (C), 154.9 (CH), 130.6 (CH), 128.6 (CH), 123.9 (C, q, $J_{C\text{---}F} = 283$ Hz), 120.6 (CH), 120.5 (C), 110.4 (CH), 87.0 (C, q, $J_{C\text{---}F} = 30$ Hz), 81.5 (C), 74.2 (CH), 54.7 (CH₃), 27.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –81.7 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 346.1261, found: 346.1259. cis-4h (minor diastereomer): $[\alpha]_D^{25} +70.7$ (c 0.17, CHCl₃, 70% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.56 (1H, td, J = 7.8, 1.5 Hz, Ar), 7.40 (1H, ddd, J = 8.2, 7.4, 1.7 Hz, Ar), 7.09 (1H, dd, J = 2.1, 0.6 Hz, N□CHO), 7.00 (1H, td, J = 7.5, 1.2 Hz, Ar), 6.98 (1H, dd, J = 7.2, 2.4 Hz, Ar), 5.23 (1H, dd, J = 2.1, 0.9 Hz, CH), 3.89 (3H, s, CH₃), 1.54 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.2 (C), 156.6 (C), 153.6 (CH), 131.3 (CH), 128.2 (CH), 123.3 (C, q, $J_{C\text{---}F} = 283$), 123.0 (C), 120.6 (CH), 111.9 (CH), 87.6 (C, q, $J_{C\text{---}F} = 32$ Hz), 82.4 (C), 75.5 (CH), 55.2 (CH₃), 27.8 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –72.4 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₆H₁₉F₃NO₄⁺: 346.1261, found: 346.1259.

tert-Butyl 5-(2-Bromophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4i). White solid (122.8 mg, >95% from 79.0 mg of 1i). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-4i (major diastereomer, 91% ee): major enantiomer, $t_r = 5.8$ min, minor enantiomer, $t_r = 9.3$ min; dr trans:cis >99:1. trans-(4*S*,5*S*)-4i (major diastereomer): Mp: 96–99 °C; $[\alpha]_D^{25} +190.2$ (c 0.54, CHCl₃, 91% ee); (two possible rotamers are observed) ¹H NMR (300 MHz, CDCl₃) δ 7.74 (1H, unresolved d, J = 7.4 Hz, Ar), 7.60 (1H, dd, J = 7.8, 1.2 Hz, Ar), 7.38 (1H, ddd, J = 7.9, 7.3, 1.3 Hz, Ar), 7.24 (1H, ddd, J = 8.0, 7.4, 1.7 Hz, Ar), 7.13 (1H, d, J = 1.8 Hz, N□CHO), 5.35 (1H, bs, CH), 1.22 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.3 (C), 154.8 (CH), 136.1 (C), 134.5 (CH), 130.6 (CH), 130.3 (CH), 127.4 (CH), 123.7 (C, q, J = 286 Hz), 120.8 (C), 88.5 (C, q, $J_{C\text{---}F} = 30$ Hz), 82.6 (CH), 74.0 (CH), 27.2 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –79.0 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₆BrF₃NO₃⁺: 394.0260, found: 394.0251. For the X-ray structure of 4i, see Figure S1 in the Supporting Information.

tert-Butyl 5-(3,4-Dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4j). Colorless oil (95.1 mg, >95% from 61.0 mg of 1j). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-4j (major diastereomer, 94% ee): major enantiomer, $t_r = 6.7$ min, minor enantiomer, $t_r = 7.5$ min; cis-4j (minor diastereomer, 85% ee): major enantiomer, $t_r = 14.9$ min, minor enantiomer, $t_r = 17.2$ min; dr trans:cis = 53:47. trans-(4*S*,5*S*)-4j (major diastereomer): $[\alpha]_D^{25} +131.8$ (c 0.48, CHCl₃, 94% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.57 (1H, d, J = 1.8 Hz, Ar), 7.47 (1H, d, J = 8.4 Hz, Ar), 7.33 (1H, ddd, J = 8.4, 2.2, 0.8 Hz, Ar), 7.19 (1H, d, J = 2.1 Hz, N□CHO), 5.06 (1H, d, J = 2.1 Hz, CH), 1.13 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.0 (C), 155.0 (CH), 134.2 (C), 132.9 (C), 131.1 (C), 130.5 (CH), 128.7 (CH, q, $J_{C\text{---}F} = 1.9$ Hz), 125.8 (CH, q, $J_{C\text{---}F} = 1.7$ Hz), 123.5 (C, q, $J_{C\text{---}F} = 283$ Hz), 86.5 (C, q, $J_{C\text{---}F} = 30$ Hz), 83.4 (C), 74.6 (CH), 27.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –80.4 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₅Cl₂F₃NO₃⁺: 384.0376, found: 384.0371. cis-4j (minor diastereomer): $[\alpha]_D^{25} +68.2$ (c 0.45, CHCl₃, 85% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.84 (1H, brs, Ar), 7.60–7.50 (2H, m, Ar), 7.11 (1H, d, J = 2.4 Hz, N□CHO), 4.94 (1H, dd, J = 2.4, 0.9 Hz, CH), 1.58 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) 165.1 (C), 153.8 (CH), 135.4 (C), 134.4 (C), 133.3 (C), 130.9 (CH), 128.7 (CH), 125.8 (CH), 122.6 (C, q, $J_{C\text{---}F} = 283$ Hz), 86.9 (C, q, $J_{C\text{---}F} = 30.8$ Hz), 84.1 (CH), 77.4 (CH), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –75.2 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₅H₁₅Cl₂F₃NO₃⁺: 384.0376, found: 384.0371.

tert-Butyl 5-(Thiophen-2-yl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4k). Yellow oil (87.1 mg, >95% from 48.9 mg of 1k). HPLC (Lux Cellulose-4, hexane:iPrOH 98:2, 1 mL/min): trans-

(4*S*,5*S*)-4k (major diastereomer, 97% ee): major enantiomer, $t_r = 7.7$ min, minor enantiomer, $t_r = 9.3$ min, cis-4k (minor diastereomer, 91% ee): major enantiomer, $t_r = 15.3$ min, minor enantiomer, $t_r = 17.7$ min; dr trans:cis = 62:38. trans-(4*S*,5*S*)-4k (major diastereomer): $[\alpha]_D^{25} +127.4$ (c 0.49, CHCl₃, 97% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.34 (1H, dd, J = 5.1, 1.2 Hz, Ar), 7.16–7.11 (2H, m, Ar, N□CHO), 7.02 (1H, dd, J = 5.1, 3.6 Hz, Ar), 5.06 (1H, d, J = 2.1 Hz, CH), 1.14 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.0 (C), 154.6 (CH), 132.8 (C), 127.5 (CH), 127.3 (CH, q, $J_{C\text{---}F} = 2.0$ Hz, Ar), 126.5 (CH), 123.3 (C, q, $J_{C\text{---}F} = 283$ Hz), 86.3 (C, q, $J_{C\text{---}F} = 32$ Hz), 82.9 (C), 75.0 (CH), 27.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –81.8 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₃H₁₅F₃NO₃⁺: 322.0719, found: 322.0713. cis-4k (minor diastereomer): $[\alpha]_D^{25} +164.7$ (c 0.49, CHCl₃, 91% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.41 (1H, dd, J = 5.1, 1.3 Hz, Ar), 7.39–7.38 (1H, m, Ar), 7.09 (1H, d, J = 2.4 Hz, N□CHO), 7.08 (1H, t, J = 3.7 Hz, Ar), 5.08 (1H, dd, J = 2.4, 0.9 Hz, CH), 1.55 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.0 (C), 153.9 (CH), 137.7 (C), 127.4 (CH), 127.3 (CH), 127.2 (CH), 122.5 (C, q, $J_{C\text{---}F} = 283$ Hz), 86.4 (C, q, $J_{C\text{---}F} = 32$ Hz), 83.7 (C), 78.2 (CH), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –75.5 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₃H₁₅F₃NO₃⁺: 322.0719, found: 322.0713.

tert-Butyl 5-Phenethyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (4l). Yellow oil (71.2 mg, 83% from 50.0 mg of 1l). HPLC (Chiralpak AY-H, hexane:iPrOH 95:5, 1 mL/min): trans-(4*S*,5*S*)-4l (major diastereomer, 84% ee): minor enantiomer, $t_r = 5.2$ min, major enantiomer, $t_r = 7.0$ min; cis-4l (minor diastereomer, 87% ee): minor enantiomer, $t_r = 8.7$ min, major enantiomer, $t_r = 12.6$ min; dr trans:cis = 72:28. trans-(4*S*,5*S*)-4l (major diastereomer): $[\alpha]_D^{25} +51.2$ (c 0.86, CHCl₃, 84% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.19 (1H, m, Ar), 7.17–7.13 (2H, m, Ar), 7.00 (1H, d, J = 2.2 Hz, N□CHO), 4.88 (1H, d, J = 2.3 Hz, CH), 2.75 (2H, t, J = 8.9 Hz, CH₂), 2.38–2.27 (1H, m, CH), 2.22–2.11 (1H, m, CH), 1.47 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 166.5 (C), 154.8 (CH), 140.1 (C), 128.5 (CH), 128.0 (CH), 126.4 (CH), 124.3 (C, q, $J_{C\text{---}F} = 282$ Hz), 85.7 (C, q, $J_{C\text{---}F} = 30$ Hz), 83.4 (C), 72.1 (CH), 31.3 (CH₂), 28.6 (CH₂), 27.9 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –79.9 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₇H₂₁F₃NO₃⁺: 344.1468, found: 344.1472. cis-4l (minor diastereomer): $[\alpha]_D^{25} +52.1$ (c 0.59, CHCl₃, 87% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.35–7.29 (2H, m, Ar), 7.26–7.17 (3H, m, Ar), 7.01 (1H, d, J = 2.2 Hz, N□CHO), 4.71 (1H, d, J = 1.7 Hz, CH), 2.81–2.66 (2H, m, CH₂), 2.46–2.36 (1H, m, CH), 2.30–2.17 (1H, m, CH), 1.50 (9H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 165.7 (C), 154.7 (CH), 139.7 (C), 128.7 (CH), 128.2 (CH), 126.6 (CH), 123.7 (C, q, $J_{C\text{---}F} = 284.3$ Hz), 86.9 (C, q, $J_{C\text{---}F} = 29$ Hz), 83.2 (CH), 73.2 (C), 35.7 (CH₂), 28.4 (CH₂), 27.7 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ –74.6 (s, CF₃); HRMS (ESI) m/z: [M + H]⁺ calcd for C₁₇H₂₁F₃NO₃⁺: 344.1468, found: 344.1472.

General Procedure for the Enantioselective Formal [3 + 2] Cycloaddition Reaction with Methyl 2-Isocyno-2-phenylacetate. Squaramide VIII (6.8 mg, 0.0125 mmol) and silver oxide (1.5 mg, 0.0063 mmol) were introduced in a round-bottom flask followed by MTBE (2 mL) and trifluoroacetophenone 1 (0.25 mmol). The flask was closed with a stopper and introduced in a bath at –20 °C. After 5 min, methyl 2-isocyno-2-phenylacetate (2c, 40 μL, 0.33 mmol) was added and the mixture was stirred at –20 °C until consumption of the trifluoroacetophenone 1 (TLC). After this time, the reaction mixture was filtered through a short pad of silica gel and concentrated under reduced pressure. Compounds 5 were quickly hydrolyzed during slow column chromatography, so separation of both diastereomers by this procedure was not possible.

The racemic product was obtained using a similar procedure using the catalyst 3-((3,5-bis(trifluoromethyl)phenyl)amino)-4-((3-(dimethylamino)propyl)amino)cyclobut-3-ene-1,2-dione and silver oxide.

Methyl 4,5-Diphenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5a). Yellow oil (76.9 mg, 89% from 43.0 mg of 1a). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-5a

(minor diastereomer): major enantiomer, $t_r = 8.4$ min, minor enantiomer, $t_r = 6.7$ min; cis-5a (major diastereomer, 90% ee): major enantiomer, $t_r = 18.3$ min, minor enantiomer, $t_r = 12.3$ min; dr trans:cis = 15:85. cis-5a (major diastereomer): $[\alpha]_D^{25} -5.3$ (c 1.0, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.46–7.41 (3H, m, Ar), 7.43 (1H, s, N□CHO), 7.15–7.08 (2H, s, Ar), 7.03 (5H, s, Ar), 3.98 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.6 (C), 153.2 (CH), 134.4 (C), 130.6 (C), 128.7 (CH), 128.3 (CH), 127.8 (CH), 127.6 (CH), 127.51 (CH), 127.46 (CH), 123.7 (C, q, $J_{C\text{F}} = 283$ Hz), 92.6 (C, q, $J_{C\text{F}} = 29$ Hz), 86.1 (C), 53.4 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.9 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₈H₁₅F₃NO₃⁺: 350.0999, found: 350.0995. trans-5a (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.92 (2H, dd, $J = 8.1, 3.0$ Hz, Ar), 7.72 (2H, dd, $J = 8.0, 3.0$ Hz, Ar), 7.50–7.35 (7H, m, Ar, N□CHO), 3.14 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.3 (s, CF₃).

Methyl 5-(4-Methoxyphenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5c). Yellow oil (40.3 mg, 42% from 51.0 mg of 1c). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-5c (minor diastereomer): major enantiomer, $t_r = 8.6$ min, minor enantiomer, $t_r = 12.1$ min; cis-5c (major diastereomer, 89% ee): major enantiomer, $t_r = 25.6$ min, minor enantiomer, $t_r = 18.5$ min; dr trans:cis = 21:79. cis-5c (major diastereomer): $[\alpha]_D^{25} -12.3$ (c 1.7, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.41 (1H, s, N□CHO), 7.34 (2H, d, $J = 8.4$ Hz, Ar), 7.05–7.03 (5H, s, Ar), 6.62 (2H, d, $J = 9.0$ Hz, Ar), 3.97 (3H, s, CH₃), 3.68 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.7 (C), 159.6 (C), 153.2 (CH), 134.6 (C), 129.7 (C), 129.0 (CH), 128.3 (C), 127.8 (CH), 127.5 (CH), 123.7 (C, q, $J_{C\text{F}} = 283$ Hz), 112.9 (CH), 92.6 (C, q, $J_{C\text{F}} = 28.5$ Hz), 86.1 (C), 55.0 (CH₃), 53.3 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -73.28 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₉H₁₇F₃NO₄⁺: 380.1104, found: 380.1106. trans-5c (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.93–7.90 (2H, m, Ar), 7.62 (2H, d, $J = 8.7$ Hz, Ar), 7.44 (1H, s, N□CHO), 6.96 (2H, d, $J = 9.0$ Hz, Ar), 3.84 (3H, s, CH₃), 3.19 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.6 (s, CF₃).

Methyl 5-(4-Chlorophenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5d). Yellow oil (95.9 mg, >95% from 53.0 mg of 1d). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-5d (minor diastereomer): major enantiomer, $t_r = 8.0$ min, minor enantiomer, $t_r = 6.0$ min; cis-5d (major diastereomer, 89% ee): major enantiomer, $t_r = 15.7$ min, minor enantiomer, $t_r = 12.0$ min; dr trans:cis = 10:90. cis-5d (major diastereomer): $[\alpha]_D^{25} -8.0$ (c 0.93, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.43 (1H, s, N□CHO), 7.39 (2H, d, $J = 8.7$ Hz, Ar), 7.13–6.96 (7H, m, Ar), 3.98 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.5 (C), 153.1 (CH), 134.9 (C), 134.0 (C), 129.5 (C), 129.1 (CH), 128.6 (CH), 128.0 (CH), 127.8 (CH), 127.3 (CH), 123.5 (C, q, $J_{C\text{F}} = 283$ Hz), 92.2 (C, q, $J_{C\text{F}} = 29$ Hz), 86.1 (C), 53.5 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -73.2 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₈H₁₄ClF₃NO₃⁺: 384.0609, found: 384.0609. trans-5d (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 8.00 (2H, d, $J = 8.1$ Hz, Ar), 7.52 (2H, d, $J = 9.0$ Hz, Ar), 3.2 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -71.5 (s, CF₃).

Methyl 5-(4-Bromophenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5n). Yellow oil (87.5 mg, 82% from 63.1 mg of 5n). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 1 mL/min): trans-5n (minor diastereomer): both enantiomers 3.6 min; cis-5n (major diastereomer, 89% ee): major enantiomer, $t_r = 10.5$ min, minor enantiomer, $t_r = 8.6$ min; dr trans:cis = 13:87. cis-5n (major diastereomer): $[\alpha]_D^{25} -12.0$ (c 0.82, CHCl₃, 89% ee, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.37 (1H, s, N□CHO), 7.26 (2H, d, $J = 8.5$ Hz, Ar), 7.17 (2H, d, $J = 9.0$ Hz, Ar), 7.04–6.90 (5H, m, Ar), 3.91 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.5 (C), 153.1 (CH), 134.0 (C), 130.8 (CH), 129.7

(CH), 129.4 (CH), 128.7 (CH), 128.1 (CH), 127.3 (CH), 123.4 (C, q, $J_{C\text{F}} = 283$ Hz), 123.3 (C), 92.3 (C, q, $J_{C\text{F}} = 29$ Hz), 86.1 (C), 53.5 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -73.1 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₈H₁₄BrF₃NO₃⁺: 428.0104, found: 428.0107. trans-5n (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.81–7.78 (2H, m, Ar), 7.37 (1H, s, N□CHO), 3.14 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.4 (s, CF₃).

Methyl 4-Phenyl-5-(*m*-tolyl)-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5e). Yellow oil (78.5 mg, 86% from 47.0 mg of 1e). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 1 mL/min): cis-5e (major diastereomer, 90% ee): major enantiomer, $t_r = 11.4$ min, minor enantiomer, $t_r = 8.5$ min; dr trans:cis = 1:99. cis-5e (major diastereomer): $[\alpha]_D^{25} -6.5$ (c 0.69, CHCl₃, 90% ee); ¹H NMR (300 MHz, CDCl₃) δ 7.44 (1H, s, N□CHO), 7.26–7.22 (2H, unresolved m, Ar), 7.04 (5H, s, Ar), 6.98 (1H, t, $J = 7.7$ Hz, Ar), 6.91 (1H, br d, $J = 7.5$ Hz, Ar), 3.97 (3H, s, CH₃), 2.17 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.7 (C), 153.3 (CH), 137.1 (C), 134.4 (C), 130.5 (C), 129.4 (CH), 128.3 (CH), 127.7 (CH), 127.5 (CH), 127.4 (CH), 124.6 (C), 123.7 (C, q, $J_{C\text{F}} = 283$ Hz), 92.6 (C, q, $J_{C\text{F}} = 29$ Hz), 86.1 (C), 53.3 (CH₃), 21.2 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.8 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₉H₁₇F₃NO₃⁺: 364.1155, found: 364.1157.

Methyl 5-(3-Methoxyphenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5f). Yellow oil (75.4 mg, 86% from 51.0 mg of 1f). HPLC (Chiralpak IC, hexane:iPrOH 95:5, 1 mL/min): trans-5f (minor diastereomer): major enantiomer, $t_r = 7.5$ min, minor enantiomer, $t_r = 10.1$ min; cis-5f (major diastereomer, 89%): major enantiomer, $t_r = 19.6$ min, minor enantiomer, $t_r = 12.5$ min; dr trans:cis = 15:85. cis-5f (major diastereomer): $[\alpha]_D^{25} +5.40$ (c 0.72, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.43 (1H, s, N□CHO), 7.10–6.90 (8H, m, Ar), 6.65 (1H, ddd, $J = 7.4, 2.6, 1.7$ Hz, Ar), 3.98 (3H, s, CH₃), 3.65 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.6 (C), 158.7 (C), 153.2 (CH), 134.4 (C), 131.9 (C), 128.7 (CH), 128.4 (CH), 127.8 (CH), 127.4 (CH), 123.6 (C, q, $J_{C\text{F}} = 287$ Hz), 120.0 (CH), 114.6 (CH), 113.4 (C), 92.4 (C, q, $J_{C\text{F}} = 28$ Hz), 86.1 (C), 55.1 (CH₃), 53.4 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.9 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₉H₁₇F₃NO₄⁺: 380.1104, found: 380.1107. trans-5f (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.93–7.90 (1H, m, Ar), 7.45 (1H, s, N□CHO), 3.85 (3H, s, CH₃), 3.18 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.3 (s, CF₃).

Methyl 5-(3-Bromophenyl)-4-phenyl-5-(trifluoromethyl)-4,5-dihydrooxazole-4-carboxylate (5g). Yellow oil (86.8 mg, 81% from 63.0 mg of 1g). HPLC (Chiralpak IC, hexane:iPrOH 90:10, 1 mL/min): trans-5g (minor diastereomer): major enantiomer, $t_r = 7.0$ min, minor enantiomer, $t_r = 5.7$ min; cis-5g (major diastereomer, 88% ee): minor enantiomer, $t_r = 10.1$ min, major enantiomer, $t_r = 14.3$ min; dr trans:cis = 2:98. cis-5g (major diastereomer): $[\alpha]_D^{25} -15.4$ (c 0.92, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.51 (1H, s, Ar), 7.36 (1H, s, N□CHO), 7.32 (1H, br d, $J = 8.0$ Hz, Ar), 7.17 (1H, d, $J = 9.0$ Hz), 7.03–6.92 (5H, m, Ar), 6.88 (1H, t, $J = 8.1$ Hz, Ar), 3.91 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 168.4 (C), 153.1 (CH), 133.8 (C), 132.8 (C), 131.9 (CH), 130.6 (br, CH), 129.0 (CH), 128.7 (CH), 128.0 (CH), 127.3 (CH), 126.4 (CH), 123.4 (C, q, $J_{C\text{F}} = 283$ Hz), 121.7 (C), 92.0 (C, q, $J_{C\text{F}} = 29$ Hz), 86.2 (C), 53.5 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -72.8 (s, CF₃); HRMS (ESI) m/z : [M + H]⁺ calcd for C₁₈H₁₄BrF₃NO₃⁺: 428.0104, found: 428.0107. trans-5g (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 8.12 (1H, s, Ar), 7.93 (1H, d, $J = 9.2$ Hz, Ar), 7.80–7.70 (2H, m, Ar), 3.15 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ -71.5 (s, CF₃).

Methyl (2*S*,3*S*)-4,4,4-Trifluoro-2-formamido-3-hydroxy-3-phenylbutanoate (6a). Aqueous HCl (6 M, six drops) was added to a solution of compound 3a (54.0 mg, 0.20 mmol) in THF (1 mL). The reaction mixture was stirred at rt for 24 h. Saturated aqueous

NaHCO₃ (1 mL) and water (10 mL) were added, and the mixture extracted with EtOAc (3 × 20 mL), washed with brine (20 mL), and dried over MgSO₄. Removal of the solvent under reduced pressure afforded compound 6a as a colorless oil (58.0 mg, 95%). HPLC (Chiracel OD-H, hexane:iPrOH 90:10, 1 mL/min): trans-6a (major diastereomer, 88% ee); major enantiomer, *t_r* = 14.0 min, minor enantiomer, *t_r* = 11.0 min; cis-6a (minor diastereomer), major enantiomer, *t_r* = 8.5 min, minor enantiomer, *t_r* = 7.9 min; dr trans:cis = 96:4. trans-6a (major diastereomer): [α]_D²⁵ −23.6 (c 0.68, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 8.24 (1H, dd, *J* = 1.2, 0.7 Hz, CHO), 7.59–7.57 (2H, m, Ar), 7.42–7.40 (3H, m, Ar), 6.79 (1H, d, *J* = 9.0 Hz, NH), 5.57 (1H, dd, *J* = 9.0, 0.6 Hz, CH), 4.68 (1H, bs, OH), 3.47 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 170.0 (C), 160.7 (CH), 134.4 (C), 129.6 (CH), 128.6 (CH), 126.1 (CH), 123.9 (C, q, *J*_{CDF} = 283 MHz), 78.20 (C, q, *J*_{CDF} = 30 Hz), 53.5 (CH), 52.9 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −75.8 (s, CF₃); HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₂H₁₃F₃NO₄⁺: 292.0791, found: 292.0798. cis-6a (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 4.85 (d, *J* = 10.5 Hz, CH), 3.54 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −76.4 (s, CF₃).

Methyl (2S,3S)-3-(3-Bromophenyl)-4,4,4-trifluoro-2-formamido-3-hydroxybutanoate (6g). Following a procedure similar to that used for the synthesis of compound 6a, from compound 3g (42.3 mg, 0.12 mmol) was obtained formamide 6g as a colorless oil (42.6 mg, 95%). HPLC (Chiralpak AY-H, hexane:iPrOH 95:5, 1 mL/min): trans-6g (major diastereomer, 91% ee): major enantiomer, *t_r* = 21.9 min, minor enantiomer, *t_r* = 29.6 min; cis-6g (minor diastereomer): major enantiomer, *t_r* = 10.9 min, minor enantiomer, *t_r* = 8.7 min; dr trans:cis = 83:17. trans-6g (major diastereomer): [α]_D²⁵ +5.41 (c 0.72, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 8.25 (1H, dd, *J* = 1.0, 0.7 Hz, CHO), 7.77 (1H, bs, Ar), 7.57–7.50 (2H, m, Ar), 7.29 (1H, t, *J* = 8.0 Hz, Ar), 6.75 (1H, d, *J* = 8.8 Hz, NH), 5.52 (1H, d, *J* = 9.0 Hz, CH), 4.85 (1H, bs, OH), 3.55 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 169.7 (C), 160.8 (CH), 136.8 (C), 132.7 (CH), 130.0 (CH), 129.5 (CH), 124.9 (CH), 123.7 (C, q, *J*_{CDF} = 285 MHz), 122.9 (C), 77.8 (C, q, *J*_{CDF} = 29 MHz), 53.6 (CH), 53.1 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −75.2 (s, CF₃); HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₂H₁₂BrF₃NO₄⁺: 369.9896, found: 369.9883. cis-6g (minor diastereomer): ¹H NMR (300 MHz, CDCl₃) representative signals taken from the NMR spectra of the diastereomer mixture, δ 7.93 (1H, s, CHO), 7.82 (1H, t, *J* = 1.7 Hz, Ar), 6.16 (1H, d, *J* = 9.0 Hz, NH), 5.42 (1H, d, *J* = 9.0 Hz, CH), 3.87 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −71.5 (s, CF₃).

Methyl (2S,3S)-2-Amino-4,4,4-trifluoro-3-hydroxy-3-phenylbutanoate (7a). Aqueous HCl (6 M, six drops) was added to a solution of compound 3a (28.6 mg, 0.11 mmol) in MeOH (1 mL). The reaction mixture was stirred at rt for 24 h. Saturated aqueous NaHCO₃ (1 mL) and water (10 mL) were added, and the mixture extracted with EtOAc (3 × 20 mL), washed with brine (20 mL), and dried over MgSO₄. Removal of the solvent under reduced pressure afforded compound 7a as a colorless oil (27.6 mg, 95%). HPLC (Chiralpak AY-H, hexane:iPrOH 95:5, 1 mL/min): trans-7a (major diastereomer, 90% ee): major enantiomer, *t_r* = 15.8 min, minor enantiomer, *t_r* = 17.3 min; cis-7a (minor diastereomer): major enantiomer, *t_r* = 11.8 min; minor enantiomer, *t_r* = 9.6 min; dr trans:cis 92:8. trans-7a (major diastereomer): [α]_D²⁵ +47.9 (c 1.23, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.61–7.54 (2H, m, Ar), 7.38–7.35 (3H, m, Ar), 4.33 (1H, s, CH), 3.29 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 171.3 (C), 135.1 (C), 128.8 (CH), 128.0 (CH), 126.3 (CH, q, *J*_{CDF} = 2.0 Hz), 125.2 (C, q, *J*_{CDF} = 283 Hz), 76.4 (C, q, *J*_{CDF} = 27 Hz), 57.3 (CH), 52.0 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −75.9 (s, CF₃); HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₁H₁₃F₃NO₃⁺: 264.0842, found: 264.0851. cis-7a (minor diastereomer): ¹H NMR (300 MHz, CDCl₃) representative signals taken from the NMR spectra of the diastereomer mixture, δ 7.65–7.60 (2H, m, Ar), 7.45–7.31 (3H, m, Ar), 4.07 (1H, s, CH), 3.83 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz,

CDCl₃) δ 56.5 (CH), 52.9 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −75.0 (s, CF₃).

Methyl 2-Amino-3-(3-bromophenyl)-4,4,4-trifluoro-3-hydroxybutanoate (7g). Following a procedure similar to that used for the synthesis of compound 7a, from compound 3g (22.7 mg, 0.064 mmol), was obtained 7g (21.0 mg, 95%). HPLC (Chiralpak AD-H, hexane:iPrOH 98:2, 0.7 mL/min): trans-7g: (major diastereomer, 92% ee): major enantiomer, *t_r* = 36.5 min, minor enantiomer, *t_r* = 34.9 min. cis-7g (minor diastereomer): major enantiomer, *t_r* = 32.8 min, minor enantiomer, *t_r* = 28.9 min; dr trans:cis 93:7. trans-7g: (major diastereomer): [α]_D²⁵ +49.1 (c 0.68, CHCl₃, for the diastereomer mixture); ¹H NMR (300 MHz, CDCl₃) δ 7.77 (1H, t, *J* = 1.9 Hz, Ar), 7.55–7.48 (2H, m, Ar), 7.24 (1H, t, *J* = 7.9 Hz, Ar), 4.32 (1H, s, CH), 3.35 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 170.8 (C), 137.3 (C), 132.0 (CH), 129.7 (CH, q, *J*_{CDF} = 1.6 Hz), 129.5 (CH), 125.1 (CH, q, *J*_{CDF} = 1.6 Hz), 124.9 (C, q, *J*_{CDF} = 289 MHz), 75.9 (C, q, *J*_{CDF} = 27 Hz), 57.1 (CH), 52.2 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −75.6 (s, CF₃); HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₁H₁₂BrF₃NO₃⁺: 341.9947, found: 341.9948. For the X-ray structure of trans-7g, see Figure S2 in the Supporting Information. cis-7g (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 7.82 (1H, br s, Ar), 7.56–7.44 (2H, m, Ar), 7.31 (1H, t, *J* = 8.0 Hz, Ar), 4.00 (1H, s, CH), 3.84 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −76.6 (s, CF₃).

Methyl 2-Amino-4,4,4-trifluoro-3-hydroxy-3-methylbutanoate (7m). Following a procedure similar to that used for the synthesis of compound 7a, from compound 3m (56.2 mg, 0.16 mmol) after 72 h was obtained 7m (60.2 mg, 88%). GLC (Supelco β-dex-225, T_{column} = 60 °C (1 min) to 150 °C at 7 °C/min, and to 220 °C at 16 °C/min, trans-7m (major diastereomer, 82%): major enantiomer, *t_r* = 12.3 min, minor enantiomer, *t_r* = 13.2 min; cis-7m (minor diastereomer): enantiomer 1, *t_r* = 17.7 min, enantiomer 2, *t_r* = 17.8 min; dr trans:cis = 97:3; trans-7m (major diastereomer): [α]_D²⁵ −38.2 (c 0.98, CHCl₃, 82% ee); ¹H NMR (300 MHz, CDCl₃) δ 3.79 (4H, s, CH, CH₃ overlapped), 1.32 (3H, s, CH₃); ¹H NMR (300 MHz, DMSO-d₆, for 7m·HCl) δ 8.82 (3H, br s, NH₃), 7.47 (1H, br s, OH), 4.10 (1H, s, CH-N), 3.75 (3H, s, CH₃), 1.39 (3H, s, CH₃); ¹³C{¹H} NMR (75 MHz, CDCl₃) δ 172.2 (C), 125.8 (C, q, *J*_{CDF} = 285 MHz), 72.6 (C, q, *J*_{CDF} = 31 Hz), 55.7 (br, CH), 52.5 (CH₃), 18.1 (CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −80.6 (s, CF₃); HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₆H₁₁F₃NO₃⁺: 202.0686, found: 202.0684. cis-7m (minor diastereomer): representative signals taken from the NMR spectra of the diastereomer mixture; ¹H NMR (300 MHz, CDCl₃) δ 3.83 (3H, s, CH₃), 1.44 (3H, s, CH₃); ¹⁹F{¹H} NMR (282 MHz, CDCl₃) δ −78.6 (s, CF₃).

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.8b02808.

Copies of ¹H, ¹³C, and ¹⁹F NMR spectra, HPLC chromatograms, and X-ray crystallographic data of 4i and 7g (PDF)

X-ray crystallographic data of 4i (CIF)

X-ray crystallographic data of 7g (CIF)

AUTHOR INFORMATION

Corresponding Authors

*E-mail: gonzalo.blay@uv.es.

*E-mail: jose.r.pedro@uv.es.

ORCID

Gonzalo Blay: 0000-0002-7379-6789

Carlos Vila: 0000-0001-9306-1109

Jose R. Pedro: 0000-0002-6137-866X

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support from the MINECO and FEDER (CTQ2017-84900-P). Access to NMR and MS facilities from SCSIE-UV. C.V. thanks the Spanish Government for a Ramon y Cajal contract (RyC-2016-20187). A.S.-M. thanks the Generalitat Valenciana and Fondo Social Europeo for a postdoctoral grant (APOST/2016/139).

REFERENCES

- (1) (a) Bertram, A.; Pattenden, G. Microcins, Gene-encoded antibacterial peptides from enterobacteria. *Nat. Prod. Rep.* 2007, 24, 18. (b) Adams, N.; Schubert, U. S. Poly(2-oxazolines) in biological and biomedical application contexts. *Adv. Drug Delivery Rev.* 2007, 59, 1504. (c) Bertram, A.; Malucci, N.; New, O. M.; Nor, S. M. M.; Pattenden, G. Synthesis of libraries of thiazole, oxazole and imidazole-based cyclic peptides from azole-based amino acids. A new synthetic approach to bistratamides and didmolamides. *Org. Biomol. Chem.* 2007, 5, 1541. (d) Sakakura, A.; Umemura, S.; Ishihara, K. Convergent total syntheses of Fluvibactin and vibriobactin using molybdenum (VI) oxide-catalyzed dehydrative cyclization as a key step. *Chem. Commun.* 2008, 30, 3561. (e) Jin, Z. Muscarine, imidazole, oxazole and thiazole alkaloids. *Nat. Prod. Rep.* 2009, 26, 382. (f) Moraski, G. C.; Chang, M.; Villegas-Estrada, A.; Franzblau, S. G.; Mollmann, U.; Miller, M. J. Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters. *Eur. J. Med. Chem.* 2010, 45, 1703. (g) Yu, X.; Liu, Y.; Li, Y.; Wang, Q. Design, synthesis, acaricidal/insecticidal activity, and structure-activity relationship studies of novel oxazolines containing sulfone/sulfoxide groups based on the sulfonylurea receptor protein-binding site. *J. Agric. Food Chem.* 2016, 64, 3034. (h) Song, W. Y.; Jeong, D.; Kim, J.; Lee, M. W.; Oh, M. H.; Kim, H. J. Key structural elements for cellular uptake of Acinetobactin, a major siderophore of *Acinetobacter baumannii*. *Org. Lett.* 2017, 19, 500. (i) Masschelein, M.; Jenner, M.; Challis, G. L. Antibiotics from gram-negative bacteria: a comprehensive overview and selected biosynthetic highlights. *Nat. Prod. Rep.* 2017, 34, 712.
- (2) (a) Desimoni, G.; Faita, G.; Jorgensen, K. A. C₂-Symmetric chiral bis(oxazoline) ligands in asymmetric catalysis. *Chem. Rev.* 2006, 106, 3561. (b) Desimoni, G.; Faita, G.; Jorgensen, K. A. C₂-Symmetric chiral bis(oxazoline) ligands in asymmetric catalysis. *Chem. Rev.* 2011, 111, PR284. (c) O'Reilly, S.; Guiry, P. J. Recent applications of C₁-symmetric bis(oxazoline)-containing ligands in asymmetric catalysis. *Synthesis* 2014, 46, 722.
- (3) (a) Meyers, A. I. Chiral oxazolines and their legacy in asymmetric carbon-carbon bond-forming reactions. *J. Org. Chem.* 2005, 70, 6137. (b) Spengler, J.; Albericio, F. Synthesis of All the Diastereomers of 2-Amino-3-hydroxy-4,5-dimethylhexanoic Acid. *Eur. J. Org. Chem.* 2014, 2014, 44. (c) Lesniak, R. K.; Markolovic, S.; Tras, K.; Schofield, C. J. Human carnitine biosynthesis proceeds via (2S,3S)-3-hydroxy-N^ε-trimethyllysine. *Chem. Commun.* 2017, 53, 440. (d) Liu, H.; Zhang, Y.; Wei, R.; Andolina, G.; Li, X. Total synthesis of *Pseudomonas aeruginosa* 1244 Pilin Glycan via de novo synthesis of pseudamino acid. *J. Am. Chem. Soc.* 2017, 139, 13420.
- (4) (a) Hayashi, T.; Uozumi, Y.; Yamazaki, A.; Sawamura, M.; Hamashima, H.; Ito, Y. Silver(I)-catalyzed asymmetric aldol reaction of isocyanoacetate. *Tetrahedron Lett.* 1991, 32, 2799. (b) Gorla, F.; Togni, A.; Venanzi, L. M.; Albinati, A.; Lianza, F. Synthesis of an optically active platinum(II) complex containing a new terdentate P-C-P ligand and its catalytic activity in the asymmetric aldol reaction of methyl isocyanoacetate. X-ray crystal structure of [2,6-bis[(1'S,2'S)-1'-(diphenylphosphino)-2',3'-O-isopropylidene-2',3'-dihydroxypropyl]phenyl](eta.1-nitrate)platinum(II). *Organometallics* 1994, 13, 1607. (c) Longmire, J. M.; Zhang, X. Synthesis and X-ray crystal structures of palladium(II) and platinum(II) complexes of the PCP-type chiral tridentate ligand (1R,1'R)-1,3-bis[1-(diphenylphosphino)ethyl]benzene. Use in the asymmetric aldol reaction of methyl isocyanoacetate and aldehydes. *Organometallics* 1998, 17, 4374. (d) Gosiewska, S.; Veld, M. H.; de Pater, J. J. M.; Bruijninx, P. C. A.; Lutz, M.; Spek, A. L.; van Koten, G.; Klein Gebbink, R. J. M. Novel enantiopure non-C₂-symmetric NCN-pincer palladium complexes with L-proline chiral auxiliaries: mer η³-N,C,N versus square planar η⁴-N,C,N,O coordination. *Tetrahedron: Asymmetry* 2006, 17, 674. (e) Yoon, M. S.; Dowook, R.; Kim, J.; Ramesh, R.; Ahn, K. H. Cyclometalated platinum(II) complexes derived from a chiral pyridine ligand: synthesis, structure, and catalytic activity. *Bull. Korean Chem. Soc.* 2007, 28, 2045. (f) Xue, M.-X.; Guo, C.; Gong, L.-Z. Asymmetric synthesis of chiral oxazolines by organocatalytic cyclization of α-aryl isocyanoesters with aldehydes. *Synlett* 2009, 2009, 2191. (g) Sladojevich, F.; Trabocchi, A.; Guarna, A.; Dixon, D. J. A new family of Cinchona-derived amino phosphine precatalysts: application to the highly enantio- and diastereoselective silver-catalyzed isocyanoacetate aldol reaction. *J. Am. Chem. Soc.* 2011, 133, 1710. (h) Kim, H. Y.; Oh, K. Highly diastereo- and enantioselective aldol reaction of methyl α-isocyanoacetate: a cooperative catalysis approach. *Org. Lett.* 2011, 13, 1306.
- (5) (a) Zhao, M. X.; Zhou, H.; Tang, W. H.; Qu, W. S.; Shi, M. Cinchona alkaloid-derived thiourea-catalyzed diastereo- and enantioselective [3 + 2] cycloaddition reaction of isocyanoacetates to isatins: a facile access to optically active spirooxindole oxazolines. *Adv. Synth. Catal.* 2013, 355, 1277. (b) Wang, F.; Chen, J.; Huang, Y. Synthesis of optically active oxazolines by an organocatalytic isocyanoacetate aldol reaction with α-keto esters. *Synlett* 2017, 28, 1300. (c) De La Campa, R.; Ortín, I.; Dixon, D. J. Direct catalytic enantio- and diastereoselective ketone aldol reactions of isocyanoacetates. *Angew. Chem., Int. Ed.* 2015, 54, 4895. (d) Martinez-Pardo, P.; Blay, G.; Muñoz, M. C.; Pedro, J. R.; Sanz-Marco, A.; Vila, C. enantioselective synthesis of chiral oxazolines from unactivated ketones and isocyanoacetate esters by synergistic silver/organocatalysis. *Chem. Commun.* 2018, 54, 2862. For an example using a chiral auxiliary, see: (e) Hunscheid, F. J. A.; Tandon, V. K.; Rouwette, P. H. F. M.; Van Leusen, A. M. Synthesis of chiral sulfonylmethyl isocyanides, and comparison of their propensities in asymmetric induction reactions with acetophenones. *Tetrahedron* 1987, 43, 5073.
- (6) (a) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. Asymmetric construction of stereogenic carbon centers featuring a trifluoromethyl group from prochiral trifluoromethylated substrates. *Chem. Rev.* 2011, 111, 455. (b) Cahard, D.; Xu, X.; Couve-Bonnaire, S.; Pannecoucke, X. Fluorine & chirality: how to create a nonracemic stereogenic carbon-fluorine centre? *Chem. Soc. Rev.* 2010, 39, 558. (c) Ma, J.-A.; Cahard, D. Update 1 of: Asymmetric fluorination, trifluoromethylation, and perfluoroalkylation reactions. *Chem. Rev.* 2008, 108, PR1-PR43. (d) Ma, J.-A.; Cahard, D. Asymmetric fluorination, trifluoromethylation, and perfluoroalkylation reactions. *Chem. Rev.* 2004, 104, 6119. (e) Hu, J.; Zhang, W.; Wang, F. Selective difluoromethylation and monofluoromethylation reactions. *Chem. Commun.* 2009, 7465. (f) Kirk, K. L. Fluorination in medicinal chemistry: methods, strategies, and recent developments. *Org. Process Res. Dev.* 2008, 12, 305.
- (7) (a) Hiyama, T. In *Organofluorine compounds: chemistry and applications*; Yamamoto, H., Ed.; Springer: New York, 2000. (b) Begue, J.-P.; Bonnet-Delpon, D. Bioorganic and medicinal chemistry of fluorine; John Wiley and Sons: Hoboken, NJ, 2000. (c) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. *Chem. Soc. Rev.* 2008, 37, 320. (d) Fluorinated heterocyclic compounds: synthesis, chemistry, and applications; Petrov, V. A., Ed.; Wiley: Hoboken, NJ, 2009. (e) Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition. *Science* 2007, 317, 1881. (f) Furuya, T.; Kamlet, A. S.; Ritter, T. Catalysis for fluorination and trifluoromethylation. *Nature* 2011, 473, 470.
- (8) Examples of radical procedures: (a) Nagib, D. A.; MacMillan, D. W. Trifluoromethylation of arenes and heteroarenes by means of photoredox catalysis. *Nature* 2011, 480, 224. (b) Studer, A. A. "Renaissance" in radical trifluoromethylation. *Angew. Chem., Int. Ed.* 2012, 51, 8950. Examples of nucleophilic procedures: (c) Cho, E. J.;

- Senecal, T. D.; Kinzel, T.; Zhang, Y.; Watson, D. A.; Buchwald, S. L. The palladium-catalyzed trifluoromethylation of aryl chlorides. *Science* 2010, 328, 1679. (d) Liu, X.; Xu, C.; Wang, M.; Liu, Q. Trifluoromethyltrimethylsilane: nucleophilic trifluoromethylation and beyond. *Chem. Rev.* 2015, 115, 683. Examples of electrophilic procedures: (e) Charpentier, J.; Früh, N.; Togni, A. Electrophilic trifluoromethylation by use of hypervalent iodine reagents. *Chem. Rev.* 2015, 115, 650.
- (9) (a) Sanz-Marco, A.; Blay, G.; Vila, C.; Pedro, J. R. Catalytic enantioselective conjugate alkynylation of β -aryl- β -trifluoromethyl enones constructing propargylic all-carbon quaternary stereogenic centers. *Org. Lett.* 2016, 18, 3538. (b) Zhu, C.; Zhu, R.; Zeng, H.; Chen, F.; Lu, C.; Wu, W.; Jiang, H. Copper-catalyzed $C(sp^3)$ -H/ $C(sp^3)$ -H cross-dehydrogenative coupling with internal oxidants: synthesis of 2-trifluoromethyl-substituted dihydropyrrrol-2-ols. *Angew. Chem., Int. Ed.* 2017, 56, 13324. (c) Ma, H.; Zhang, X.; Chen, L.; Yu, W. A domino azidation/C-H amination approach toward trifluoromethyl substituted imidazoles. *J. Org. Chem.* 2017, 82, 11841. (d) Espinosa, M.; Herrera, J.; Blay, G.; Cardona, L.; Muñoz, M. C.; Pedro, J. R. Copper-catalysed enantioselective Michael addition of malonic esters to β -trifluoromethyl- α,β -unsaturated imines. *Org. Biomol. Chem.* 2017, 15, 3849.
- (10) (a) Ryabtsova, O.; Joossens, J.; van der Veken, P.; Vanden Berghe, W.; Augustyns, K.; de Winter, H. Novel selective glucocorticoid receptor agonists (SEGRAs) with a covalent warhead for long-lasting inhibition. *Bioorg. Med. Chem. Lett.* 2016, 26, 5032. (b) Kim, J.; Lee, I. N. Inactivation of bovine plasma amine oxidase by 1,1,1-trihalo-3-aminopropanes. *Bioorg. Chem.* 2017, 75, 265. (c) Borisova, T.; Pozdnyakova, N.; Shaitanova, E.; Gerus, I.; Dudarenko, M.; Mironets, R.; Haufe, G.; Kukhar, V. Synthesis of new fluorinated analogs of GABA, Pregabalin bioisosteres, and their effects on $[^3H]GABA$ uptake by rat brain nerve terminals. *Bioorg. Med. Chem.* 2015, 23, 4316. (d) Tsushima, T.; Kawada, K.; Ishihara; Uchida, N.; Shiratori, O.; Higaki, J.; Hirata, M. Fluorine containing amino acids and their derivatives. 7. Synthesis and antitumor activity of α - and γ -substituted methotrexate analogs. *Tetrahedron* 1988, 44, 5375. (e) Barnett, H. A.; Coe, D. M.; Cooper, T. W. J.; Jack, T. I.; Jones, H. T.; Macdonald, S. J. F.; McLay, I. M.; Rayner, N.; Sasse, R. Z.; Shipley, T. J.; Skone, P. A.; Somers, G. I.; Taylor, S.; Uings, I. J.; Woolven, J. M.; Weingarten, G. G. Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists. *Bioorg. Med. Chem. Lett.* 2009, 19, 158.
- (11) (a) Vocadlo, D. J.; Mayer, C.; He, S. M.; Withers, S. G. Mechanism of action and identification of Asp242 as the catalytic nucleophile of *Vibrio furnisii* N-acetyl- β -D-glucosaminidase using 2-acetamido-2-deoxy-5-fluoro- α -L-idopyranosyl fluoride. *Biochemistry* 2000, 39, 117. (b) Namchuk, M. N.; McCarter, J. D.; Becalski, A.; Andrews, T.; Withers, S. G. The role of sugar substituents in glycoside hydrolysis. *J. Am. Chem. Soc.* 2000, 122, 1270. (c) Resnati, G. Synthesis of chiral and bioactive fluoroorganic compounds. *Tetrahedron* 1993, 49, 9385.
- (12) (a) Kitamoto, T.; Marubayashi, S.; Yamazaki, T. Preparation and conformational study of CF_3 -containing enkephalin-derived oligopeptide. *Tetrahedron* 2008, 64, 1888. (b) Cho, J.; Irie, S.; Iwahashi, N.; Itoh, Y.; Saigo, K.; Ishida, Y. A practical synthesis of enantiopure 4,4,4-trifluoro- α -threonine from an easily available fluorinated building block. *Tetrahedron Lett.* 2015, 56, 127. (c) Lee, C.-J.; Liang, X.; Wu, Q.; Najeeb, J.; Zhao, J.; Gopalaswamy, R.; Titecat, M.; Sebbane, F.; Lemaitre, N.; Toone, E. J.; Zhou, P. Drug design from the cryptic inhibitor envelope. *Nat. Commun.* 2016, 7, 10638.
- (13) (a) Soloshonok, V. A.; Hayashi, T.; Ishikawa, K.; Nagashima, N. Highly diastereoselective aldol reaction of fluoroalkyl aryl ketones with methyl isocyanoacetate catalyzed by silver(I)/trimethylamine. *Tetrahedron Lett.* 1994, 35, 1055. (b) Soloshonok, V. A.; Kacharov, A. D.; Avilov, D. V.; Ishikawa, K.; Nagashima, N.; Hayashi, T. Transition metal/base-catalyzed aldol reactions of isocyanoacetic acid derivatives with prochiral ketones, a straightforward approach to stereochemically defined β,β -disubstituted- β -hydroxy- α -amino acids. Scope and limitations. *J. Org. Chem.* 1997, 62, 3470. (c) Soloshonok, V. A.; Kacharov, A. D.; Avilov, D. V.; Hayashi, T. Transition metal-catalyzed diastereoselective aldol reactions of prochiral ketones with methyl isocyanoacetate. *Tetrahedron Lett.* 1996, 37, 7845.
- (14) Arroniz, C.; Gil-Gonzalez, A.; Semak, V.; Escolano, C.; Bosch, J.; Amat, M. Cooperative catalysis for the first asymmetric Formal [3 + 2] cycloaddition reaction of isocyanoacetates to α,β -unsaturated ketones. *Eur. J. Org. Chem.* 2011, 2011, 3755.
- (15) Caution has to be taken during the purification of the reaction products to avoid alteration of the ee values due to the self-disproportionation of enantiomers phenomenon. See: (a) Soloshonok, V. A. Remarkable amplification of the self-disproportionation of enantiomers on achiral-phase chromatography columns. *Angew. Chem., Int. Ed.* 2006, 45, 766. (b) Soloshonok, V. A.; Roussel, C.; Kitagawa, O.; Sorochinsky, A. E. Self-disproportionation of enantiomers via achiral chromatography: a warning and an extra dimension in optical purifications. *Chem. Soc. Rev.* 2012, 41, 4180.
- (16) The structure and absolute stereochemistry of compounds 7g and 4i were determined by X-ray analysis, CCDC 1844051–1844052, respectively; see the [Supporting Information](#).
- (17) The absolute stereochemistry of the minor cis-3 and cis-4 oxazolines could not be determined. On the basis of our previous results with ketones (see ref 5d), we assume they may have the (4*S*,5*R*) configuration.
- (18) The absolute stereochemistry of compound 5 could not be determined.
- (19) Lee, C.-J.; Liang, X.; Wu, Q.; Najeeb, J.; Zhao, J.; Gopalaswamy, R.; Titecat, M.; Sebbane, F.; Lemaitre, N.; Toone, E. J.; Zhou, P. Drug design from the cryptic inhibitor envelope. *Nat. Commun.* 2016, 7, 10638.
- (20) Compounds 3 and 4 showed some tendency to hydrolyze during column chromatography, which in some cases made their purification by this technique difficult. In a reduced number of cases, the reaction products contained trace amounts of residual isocyanoacetates or their byproducts. See the NMR spectra in the [Supporting Information](#) for the possible presence of small amounts of contaminants.